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SUMMARY 
 
Inflammatory Bowel Diseases (IBD) are severe gastrointestinal (GI) disorders, including 
Crohn’s Disease (CD) and Ulcerative Colitis (UC), characterized by a chronic intestinal 
inflammatory reaction progressively causing tissue damage and a series of related major 
symptoms including defective GI motor activity, diarrhea, rectal bleeding, malabsorption, 
weight loss, fever. A plethora of factors contributes to the physiopathology of IBD, 
including genetic susceptibility, environmental factors, increased intestinal permeability 
and, above all, the establishment of an aberrant immune reaction of the Gut-Associated 
Lymphoid Tissue (GALT) to harmless antigens derived from commensal microbiota. Due 
to the complex interplay of these diverse factors, the exact cause of IBD is still unknown, 
and the appropriate treatment of IBD is still a clinical issue, since current therapeutic 
strategies are restricted to classical anti-inflammatory drugs, not leading to the complete 
resolution and often associated with different side effects. Hence, research on novel factors 
and pathways involved in the physiopathology of IBD are absolutely needed to improve 
currently available therapies. Recently, several researches have provided evidence for the 
potential effect in IBD of mediators of the enteric nervous system (ENS), demonstrating 
that modification in the contribution and role of some enteric mediators could lead to the 
pathological changes of GI motor patterns, as well as to the modulation of the local 
inflammatory event, controlling immune cell activity within the GALT.  
Angiotensin II (Ang II) and γ-aminobutyric acid (GABA) have been suggested as novel 
mediators involved in the modulation of GI motility, and, interestingly, other studies have 
pointed out their connection with inflammatory conditions, suggesting that a detailed 
investigation of these mediators could lead to their identification as novel therapeutic 
targets in inflammatory disorders, including Inflammatory Bowel Disease. Angiotensin II, 
 
4 
 
the main effector of the renin-angiotensin system (RAS), has been previously reported to 
act in the gut microenvironment as modulator of water/electrolytes absorption, glucose 
transport and bicarbonate secretion, via its action on the specific AT1 and AT2 receptors. 
However, its role in the modulation of gut motility is increasingly emerging, as Ang II 
induces enteric smooth muscle contraction in the small intestine and colon, mostly via 
modulation of the enteric tachykinergic signaling. Moreover, a series of recent studies has 
also underlined the connection between Ang II and GI inflammation, as intestinal levels of 
Ang II are higher in CD patients, and antagonists of angiotensin receptors (especially AT1) 
displayed beneficial effect in animal models of IBD. Thus, novel studies about the role of 
Ang II in health and disease could disclose its potential as therapeutic target for the 
treatment of both IBD-related GI motor dysfunction and inflammation. Hence, in the first 
part of this thesis, we explored the role of Ang II as modulator of colonic motility in 
control animals and in an animal model of IBD. We firstly evaluated different 
inflammatory markers in the IBD model, in order to characterize the extent and severity of 
ongoing inflammation, demonstrating the appearance of pathological signs associated to 
IBD as clinical symptoms (weight loss, diarrhea), macroscopic tissue damage (i.e. evident 
ulcerations, bowel wall thickening), histological damages and a significant immune 
infiltrate in the bowel wall. We then compare the effect of Ang II on the colonic 
mechanical activity in control and inflamed animals, demonstrating that Ang II mediates 
contraction of enteric colonic smooth muscle both in control and IBD animals, but its 
contractile effect is reduced in the latter. AT1 receptors were the sole responsible for Ang 
II-mediated contraction in the control animals, whilst an influence of both AT1 and AT2 
receptors have been observed in inflamed animals. Indeed, our experimental data suggest 
that reduced contraction to Ang II in experimental inflammation could be dependent on the 
inhibitory action of tonically activated AT2 receptors, counteracting the excitatory effect of 
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AT1 receptors. In detail, AT2 receptor would induce an increase in nitrergic signaling in 
the ENS, in turn resulting in a general depression of colonic contractile activity. We 
speculate that such effect could contribute to the observed reduction in colonic mechanical 
activity observed in IBD patients, and thus that pharmacological targeting of AT2 
receptors would represent a novel strategy in the treatment of motor dysfunctions in IBD.  
In the second part of this thesis, we focused on the definition of the role of the GABAergic 
system in the modulation of colonic mechanical activity in an animal model, as a potential 
starting point for a consequent exploration of its involvement in GI inflammation. Indeed, 
different reports have already established the participation of GABAergic pathways in the 
circuitry of ENS governing GI motility, disclosing its action as neuromodulator causing  
enteric smooth muscle contraction or relaxation acting on specific GABAA, GABAB and 
GABAC receptors. However, the exact significance of GABAergic modulation of GI 
function is still not completely clear, especially in the distal part of the GI tract. 
GABAergic fibers have been suggested to be part of a network of interneurons controlling 
the release of non adrenergic non cholinergic mediators responsible for smooth muscle 
relaxation in the peristaltic reflex, as well as to participate in the modulation of 
acetylcholine (ACh) and substance P (SP) release allowing smooth muscle contraction in 
peristalsis. Our experimental data added a novel level to the picture of GABAergic 
pathways in the colon, demonstrating the fine and opposite modulation of cholinergic 
signaling by differential activation of GABAA and GABAB receptors depending on GABA 
concentration. Low concentrations of GABA (10-50 μM) acting on GABAA receptors 
induced circular muscle contraction via ACh release from cholinergic motor neurons, in 
turn promoting in vitro peristaltic activity. Interestingly, experiment using the selective 
GABAA receptor antagonist bicuculline suggested that a tonic activation of GABAA 
receptor occurs in physiological conditions, potentially sustaining peristalsis. Conversely, 
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higher GABA concentrations (500μM–1mM), caused GABAB-dependent opposite effects, 
reducing ACh release via an indirect pathway involving cholinergic interneurons and thus 
causing an inhibition of in vitro peristaltic activity. The observation of concentration-
dependent effect of GABA could result of importance in pathologic conditions 
characterized by modification in content and functionality of enteric mediators, as reported 
in Inflammatory Bowel Disease. In addition, a plethora of studies recently linked the 
GABAergic system to different inflammatory diseases, including rheumatoidis arthritis, 
encephalomyelitis and dermatitis, exploring its novel role as neuroimmune modulator 
influencing immune processes as cytokine production, proliferation and maturation via 
GABAergic receptors located on immune cells. Thus, the exploration and comparison of 
the role of GABA in physiological condition and gastrointestinal disorders, as 
Inflammatory Bowel Disease, could represent a novel frontier for the definition of its role 
both in the defective bowel motor patterns in IBD as well as in the modulation of the 
inflammatory event.  
In conclusion, results present in this thesis suggest that the modulation of the colonic 
mechanical activity by Ang II and GABA would be of impact in the physiopathology of 
Inflammatory Bowel Disease, and represent a scientific rationale for a broader 
investigation of the role of these enteric mediators in gastrointestinal inflammation.  
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SOMMARIO 
Le Malattie Infiammatorie Croniche Intestinali (MICI o IBD, Inflammatory Bowel 
Disease) sono gravi patologie gastrointestinali (GI), comprendenti il morbo di Crohn (CD) 
e la colite ulcerosa (UC), caratterizzate da una reazione infiammatoria cronica associata a 
progressivi danni tissutali e una serie di sintomi, che includono disfunzione dell’attività 
motoria GI, diarrea, sanguinamento rettale, malassorbimento, perdita di peso. Diversi 
fattori contribuiscono alla fisiopatologia delle IBD, compresa la suscettibilità genetica, 
fattori ambientali, aumento della permeabilità intestinale e, soprattutto, il verificarsi di una 
reazione immunitaria anomala del Tessuto Linfoide Associato all’Intestino (GALT) contro 
antigeni “innocui” derivanti dal microbiota intestinale. Data la complessa interazione di 
questi diversi fattori, la causa esatta delle Malattie Infiammatorie Intestinali è ancora 
sconosciuta, e il loro trattamento rappresenta tutt’oggi un problema clinico, dal momento 
che che le attuali strategie terapeutiche sono limitate a classici farmaci anti-infiammatori 
che non conducono alla risoluzione completa della patologia e sono spesso associati ad 
effetti collaterali. Su queste basi, la ricerca di nuovi fattori e meccanismi coinvolti nella 
fisiopatologia delle IBD risulta assolutamente necessaria per il miglioramento delle attuali 
terapie disponibili. Recentemente, diverse ricerche hanno comprovato il potenziale 
coinvolgimento nelle IBD di mediatori del sistema nervoso enterico (SNE), la complessa 
rete neuronale che controlla la maggior parte delle funzioni intestinali, dimostrando che il 
cambiamento nel contributo e ruolo di diversi mediatori enterici potrebbe portare sia alle 
alterazioni patologiche della motilità GI nelle IBD, nonché alla modulazione dell’evento 
infiammatorio locale, controllando l'attività delle cellule immunitarie del GALT. 
Recentemente l’angiotensina II (Ang II) e l’acido γ-aminobutirrico (GABA) sono stati  
riconosciuti come nuovi mediatori coinvolti nella modulazione della motilità 
gastrointestinale, e, inoltre, altri studi ne hanno evidenziato la connessione con differenti 
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condizioni infiammatorie, suggerendo che una ricerca approfondita sul ruolo di tali 
mediatori potrebbe condurre alla loro identificazione come nuovi target terapeutici in 
condizioni infiammatorie, tra cui le Malattie Infiammatorie Croniche Intestinali.  
L’Angiotensina II, principale effettore del sistema renina-angiotensina (RAS), è stata 
precedentemente identificata come modulatore dell’assorbimento di acqua/elettroliti, del 
trasporto del glucosio e della secrezione di bicarbonato nel microambiente intestinale, 
tramite la sua azione sui recettori specifici AT1 e AT2. Tuttavia, diversi studi stanno 
dimostrando sempre più nel dettaglio il suo ruolo emergente nella modulazione della 
motilità intestinale, capace di indurre contrazione della muscolatura liscia enterica nel 
piccolo e grande intestino, in particolare attraverso la modulazione del segnale 
tachichinergico enterico. Inoltre, una serie di studi recenti ha sottolineato il collegamento 
tra Ang II e infiammazione gastrointestinale, dato che i livelli intestinali di Ang II sono più 
elevati nei pazienti IBD e antagonisti dei recettori dell'angiotensina (in particolare AT1) 
inducono un miglioramento della condizione infiammatoria in modelli animali di IBD. 
Nuovi studi sul ruolo dell’Ang II in condizioni fisiologiche e patologiche potrebbero 
dunque rivelare il suo potenziale come target terapeutico per il trattamento delle IBD, sia 
nella disfunzione motoria associata alle IBD sia nell’evento infiammatorio. 
Nella prima parte di questa tesi, il ruolo dell’Ang II come modulatore della motilità del 
colon è stato esplorato in animali controllo e in un modello animale di IBD. Inizialmente, 
sono stati valutati differenti marker infiammatori nel modello IBD, in modo da 
caratterizzare la severità dell’infiammazione in corso, dimostrando la comparsa di segni 
patologici associati alle IBD quali sintomi clinici (perdita di peso, diarrea), danno tissutale 
macroscopico  (ulcerazioni evidenti, ispessimento della parete intestinale), danni istologici 
e una infiltrazione significativa di cellule immunitarie nel tessuto intestinale. Abbiamo 
quindi comparato gli effetti dell’Ang II sull’attività meccanica del colon in animali 
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controllo e infiammati. Inizialmente, è stato osservato che l’Ang II media contrazione della 
muscolatura liscia del colon sia negli animali controllo e infiammati, ma il suo effetto 
contrattile risulta ridotto in questi ultimi. I recettori AT1 sono risultati i soli responsabili 
della contrazione indotta dall’Ang II negli animali controllo, mentre l'influenza sia dei 
recettori AT1 e AT2 è stata evidenziata negli animali infiammati. Infatti, i nostri dati 
sperimentali suggeriscono che la riduzione della contrazione indotta dall’Ang II nel corso 
dell’infiammazione sperimentale potrebbe dipendere dall'azione inibitoria dei recettori 
AT2 i quali, tonicamente attivati, contrasterebbero l'effetto eccitatorio dei recettori AT1. 
Nel dettaglio, i recettori AT2 sarebbero associati ad un aumento del segnale nitrergico nel 
sistema nervoso enterico, con conseguente inibizione dell’attività contrattile del colon. È 
possibile ipotizzare che tale effetto osservato potrebbe contribuire alla riduzione 
dell’attività meccanica colon osservata nei pazienti IBD, e che dunque un trattamento 
farmacologico mirato sui recettori AT2 potrebbe rappresentare una nuova strategia 
terapeutica per le disfunzioni motorie nelle IBD. 
Nella seconda parte di questa tesi, ci siamo concentrati sulla definizione del ruolo del 
sistema GABAergico nella modulazione dell'attività meccanica del colon in un modello 
animale, come potenziale punto di partenza per la caratterizzazione del suo potenziale 
coinvolgimento nel contesto dell’infiammazione intestinale. Diversi studi hanno già 
suggerito la partecipazione di pathway GABAergici nei circuiti del SNE responsabili della 
regolazione della motilità gastrointestinale, rivelando la sua azione come neuromodulatore 
causante contrazione o rilasciamento del muscolo liscio enterico mediante attivazione dei 
recettori specifici GABAA, GABAB e GABAC. Nonostante ciò, l'esatto contributo del 
sistema GABAergico della modulazione delle funzioni GI risulta ancora non 
completamente chiarita, soprattutto nella parte distale del tratto GI. Fibre neurali 
GABAergiche farebbero parte di una rete di interneuroni che controllerebbero il rilascio di 
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mediatori non adrenergici non colinergici responsabili del rilasciamento del muscolo liscio 
enterico nel riflesso peristaltico, e inoltre parteciperebbero nella modulazione del rilascio 
di acetilcolina (ACh) e sostanza P (SP) necessari per la contrazione della muscolatura 
liscia nella peristalsi. I nostri dati sperimentali aggiungono un nuovo livello nel quadro dei 
meccanismi  GABAergici nel colon, dimostrando  la capacità del GABA di modulare  il 
segnale colinergico attraverso l’attivazione differenziale di recettori GABAA o GABAB in 
funzione della concentrazione di GABA. Basse concentrazioni di GABA (10-50 μM) 
agirebbero sui recettori GABAA, inducendo contrazione del muscolo liscio circolare del 
colon attraverso il rilascio di ACh da motoneuroni colinergici, promuovendo in ultimo 
l’attività peristaltica indotta in vitro. Da notare che i dati sugli effetti dell’antagonista 
selettivo del recettore GABAA, bicucullina, suggerirebbero una attivazione tonica dei 
recettori GABAA in condizioni fisiologiche, potenzialmente associata al sostenimento 
dell’attività peristaltica. Al contrario, concentrazioni più elevate di GABA (500μM - 
1mM), causavano effetti opposti dipendenti dall’attivazione dei recettori GABAB, 
riducendo il rilascio di ACh tramite un pathway neurale indiretto che coinvolge 
interneuroni colinergici, e provocando così inibizione della attività peristaltica in vitro. 
L'osservazione di un effetto concentrazione-dipendente del GABA potrebbe rivelarsi 
cruciale in condizioni patologiche caratterizzate da cambiamenti nei livelli e nella 
funzionalità di mediatori enterici, come riportato nelle Malattie Infiammatorie Croniche 
Intestinali. Inoltre, diversi studi hanno recentemente associato il sistema GABAergico a 
diverse condizioni infiammatorie, tra cui artrite reumatoide, encefalomielite e dermatite, 
esplorando il suo ruolo come modulatore neuroimmunitario capace di influenzare processi 
quali produzione di citochine, proliferazione e maturazione, attraverso recettori 
GABAergici situati sulle cellule immunitarie. Dunque, la ricerca e il confronto del ruolo 
del GABA in condizioni fisiologiche e patologiche gastrointestinali, quali le IBD, potrebbe 
 
11 
 
condurre alla definizione del suo ruolo sia nelle modificazioni patologiche dell’attività 
motoria intestinale nelle IBD che nella modulazione dell'evento infiammatorio correlato a 
queste patologie. In conclusione, i risultati esposti in questa tesi suggeriscono che la 
modulazione dell’attività meccanica intestinale da parte dell’Ang II e del GABA potrebbe  
contribuire alla fisiopatologia delle Malattie Infiammatorie Croniche Intestinali, e 
rappresentare una base razionale per un'indagine più ampia del ruolo di questi mediatori 
enterici nel contesto dell’infiammazione intestinale. 
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 CHAPTER 1 
Inflammatory Bowel Disease:  
pathogenesis, treatment and animal models 
 
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory disorders 
affecting the gastrointestinal (GI) tract, including Crohn's Disease (CD) and Ulcerative 
Colitis (UC). The etiology of these disorders is not yet entirely clear due to their 
multifactorial origin, with an interplay of contributing factors including genetic 
susceptibility, immune dysfunctions, environmental factors (i.e. infections, lifestyle) 
(Xavier & Podolsky, 2007; Fig.1). IBD have a peak onset between 15 and 30 years of age, 
although they can occur at any age. Both UC and CD have a bimodal distribution of age, 
with a second smaller peak that occurs in individuals aged between 50 and 70 years of age 
(Andres et al, 1999). Males and females are equally affected, although ulcerative colitis is 
slightly more common in males, while Crohn's disease is slightly more common in women 
(Loftus et al., 2003, Andres et al., 1999). IBD patients display a chronic GI inflammation 
with periodic flare-ups characterized by severe symptoms as rectal bleeding, severe 
diarrhea, abdominal pain, fever and weight loss.  
 
 
Figure 1: Multiple factors involved in IBD pathogenesis 
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The histological examination of biopsies obtained from patients with active disease reveals 
the presence of a large number of leukocytes, such as polymorphonuclear leukocytes, 
lymphocytes and monocytes within the intestinal wall. Coinciding with this inflammatory 
infiltrate, extensive intestinal lesions including ulcerations, edema, loss of goblet cells, 
bowel wall thickening occur (Hendrickson et al., 2002), progressively affecting the GI 
functions. Of note, patients with mild to moderate IBD displayed dysfunctions in intestinal 
motility, as a reduction of spontaneous contractions (Koch et al., 1988) and variations in 
the colonic transit (Reddy et al., 1991), even in phase of remission of the pathology. IBD-
related motor dysfunctions importantly contribute to morbidity and quality of life issues of 
patients and, interestingly, several symptoms of IBD, including diarrhoea, malabsorption 
and weight loss, could be attributed to the alteration of motor function of the intestine (De 
Schepper et al., 2008). Changes in the neural signaling within the enteric nervous system 
(ENS), the semi-autonomous neuronal network primarily involved in the regulation of GI 
motility, together with enteric smooth muscle cells damage have been suggested as 
contributing factors in IBD-associated dysmotility (De Schepper et al., 2008; Mawe et al., 
2015), although to date the exact cause of motor disorders in IBD are largely unclear. 
Regarding the different factors involved in IBD physiopathology, genetics play a role in 
susceptibility as proven by epidemiological studies addressing IBD as genetically complex 
disorders (Hanauer, 2006). Several susceptible sites potentially associated with CD or UC 
have been identified. In particular, the gene NOD2 (nucleotide-binding oligomerization 
domain 2), also known as CARD15 (Caspase Activation and Recruitment Domain). was 
the first gene to be clearly associated with IBD (Hugot et al., 2001) and more than 60 
mutations have been also identified, 3 of which have been linked to the development of 
Crohn's disease (Rowe, 2005). The product of this gene is a cytoplasmatic protein involved 
in the innate immune system, with a role in recognizing bacterial products; its mutation 
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would result in an altered intracellular processing of the bacterial products and 
consequently alteration in the immune response (Shih et al., 2008). Another factor 
contributing to the physiopathology of IBD is a defect in the intestinal mucosal barrier 
function, leading to increased permeability (Baumgart et al., 2007) associated with a 
greater adherence of the bacteria. In turn, abnormal exposure of enteric immune system to 
bacterial products may result in aberrant immune activation and inflammation (Peyrin-
Biroulet et al., 2008; Sartor, 2008; Shih et al., 2008).  
Accordingly, increasing evidence have demonstrated the disturbance in physiologic 
immune response in the gut as the most important factor in IBD, revealing an aberrant 
immune response to the autologous commensal microbiota as the major mechanism 
governing the sustained inflammation in IBD. The GI tract hosts the largest immune 
system in the body. The Gut-Associated Lymphoid Tissue (GALT) constituted a highly 
complex and fine regulated network, essential to properly face the continuous antigenic 
stimulation occurring in the GI tract (Koboziev et al., 2010; Fig.2). The immune activity 
within the GALT is essential to maintain tolerance to “harmless” antigens in the enteric 
milieu, i.e. food antigens and commensal microbiota antigens, as well as to ensure a proper 
immune response to the “harmful” antigens deriving from pathogens. Briefly, in absence of 
an infection, immune homeostasis is assured by a specialized enteric population of DCs 
(CD103
+
 DCs) capable of inducing the differentiation of immunosuppressive T Regulatory 
cells (TRegs); TRegs activity sustains the tolerogenic state in the GALT avoiding the 
establishment of an improper inflammatory response to harmless stimuli mediated by 
aberrant activation of T helper lymphocytes (Thelper 1, Thelper 17, Thelper 2; Th1,Th17, 
Th2), primarily via secretion of immunosuppressive cytokines as Transforming Growth 
Factor (TGF)-β and IL-10 (Nutsch et al., 2012). On the contrary, a pathogenic infection 
triggers populations of DCs to orchestrate an immune response activating effector T-cells, 
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including Th1, Th2 and Th17 cells (Janeway et al., 2001), which release pro-inflammatory 
cytokines as TNF-α, IFN-γ, IL-5, IL-17. Hence, defects in these regulatory mechanisms 
could result in the occurrence of the chronic inflammatory event in IBD, which is 
accordingly associated with an improper T-cell over-reaction and a pathological and 
chronic increase in pro-inflammatory mediators, as TNF-α, IFN-γ and IL-5 (Strober & 
Fuss, 2011). 
 
Figure 2: Schematic representation of the Gut-Associated Lymphoid Tissue. 
 Abbreviations: IEL: intraepithelial lymphocytes; IgA: Immunoglobulin A 
(Adapted from Pereira et al., 2014) 
 
 
The cell-mediated immune response occurring in IBD can follow two different pathways, 
characterizing the two forms of the disease (Fig. 3): a Th1 response associated with 
Crohn's disease, or a Th2 response associated with Ulcerative Colitis (Podolsky, 2002; 
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Fig.3). The activation of naive T cells is promoted by Antigen-presenting Cells (APCs), 
such as dendritic cells and macrophages, and the cytokines signaling influences the 
switching to Th1 or Th2 (Abreu, 2002). Overproduction of IL-12 shifts the immune 
response toward Th1 in Crohn’s Disease. This response is characterized by an increased 
secretion of interferon-γ, TNF-α, IL-1β, and IL-6 (Abreu, 2002; Bouma et al., 2003), 
leading to transmural inflammation and tissue damages. On the other hand, activation of 
Th2 cells is associated with increased secretion of IL-4, IL-5, IL-10 and IL-13, associated 
with a mucosal inflammation. However, ulcerative colitis was recently linked with a 
pathological activity of a population of Natural Killer T cells, adding a novel layer of 
complexity to the exact definition of the Th2 response in UC (Strober & Fuss, 2011). It has 
been also suggested that inflammation in IBD may be due to a lack of TRegs (Boehm et 
al., 2012), leading to severe loss of tolerance to the commensal microbiota antigens, 
resulting in proliferation of immune cells and cytokine production. Indeed, IL-10 knockout 
mice spontaneously develop colitis, and treatment with TGF-β and IL-10 heals 
experimental colitis in animal model (Abreu, 2002).  
 
 
Figure 3: T helper cells and related cytokines involved in the physiopathology of                                       
Inflammatory Bowel Disease. 
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Currently there is no effective cure for IBD, and available therapy aims to subside chronic 
inflammation mainly via the use of classic anti-inflammatory drugs as 5-aminosalicylic 
acid and immunomodulators such as azathioprine, mercaptopurine, methotrexate (Randall 
et al., 2015). Also, monoclonal antibodies Infliximab and Adalimumab targeting TNF-α 
have reported to maintain remission of the symptoms in IBD patients (Furfaro et al., 2015). 
However, most of drugs for IBD treatment are temporarily effective and associated with 
different side effects, especially during long-term treatment, including bone marrow 
defects, liver toxicity, pancreatitis, opportunistic infections and lymphomas (Triantafillidis 
et al., 2011). Also, besides of drugs directly contrasting the inflammatory event, treatment 
of gastrointestinal motor disorders in IBD patients are largely neglected. As 
aforementioned, although intestinal motor dysfunctions are likely important contributors in 
IBD symptomatology, few researches addressed the exact cause of dysmotility in IBD, and 
treatment of motor abnormalities solely include classical drugs employed in the therapy for 
functional GI disorders (i.e. prokinetics).  The definition of a strategy targeting the specific 
pathways underlying GI aberrant motor patterns in IBD, likely involving changes in the 
action of enteric mediators within the neuronal network of ENS, is almost overlooked (De 
Schepper et al., 2008). Thus, the identification of novel players in the physiopathology of 
IBD controlling both immune activity and intestinal motor defects could lead to the 
development of new effective therapies for IBD.  
Over the years, the development of different experimental models of IBD has allowed a 
closer investigation of the early events, interactions between different components and  
identification of major immunological pathways in IBD (Kiesler et al., 2015; Fig.4). 
Animal models have increasingly provided important information for understanding the 
multifaceted inflammatory mechanism characterizing these pathologies, and represent 
important tools for the definition of novel therapeutic strategies. In general, an ideal animal 
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model of IBD should present some key features: the gut should have morphological 
alterations, inflammation, symptoms and signs, pathophysiology and clinical course similar 
or identical to those found in humans. However, this is rarely possible due to the 
complexity of the disease and the high genetic and environmental influences that determine 
a high variability in its onset and clinical course. Thus, no single model seems able to 
mimic the complexity of human IBD, but each model provides valuable insights into one 
or another major aspect of disease. Animal models of IBD are generally divided into four 
main classes (Mizoguchi, 2012): 1) genetically engineered models, especially mice with 
deletion of specific genes representing key IBD susceptibility genes (i.e. IL-10 knockout 
mice); 2) spontaneous-developing colitis models, as the C3H/HeJBir mouse; 3) 
chemically-induced models, containing  numerous models in which colitis is induced by 
administration of a compound, as trinitrobenzenesulfonic acid (TNBS), 
dinitrobenzensulfonic acid (DNBS), dextran sulfate sodium (DSS), oxalozone; 4) the 
adoptive cell transfer models in immunocompromised animals, where transfer of naive T 
lymphocytes into T and B cell deficient mice induces severe colonic inflammation in the 
recipient, resembling IBD-like lesions.  
Adoptive transfer models have provided numerous information to understand the adaptive 
immune mechanism involved in the pathogenesis of IBD. TNBS model has been used to 
assess and develop anti-IL-12p40 therapy that is currently applying to human IBD, and IL-
10 knockout model has provided significant contributions for the role of probiotics in IBD 
(Sheil et al., 2006). Also, DSS model has been useful for dissecting the mechanism of 
inflammation-associated epithelial barrier dysfunction. Noticeably, recently, DNBS model 
have been used for investigation of the pathophysiology of intestinal motor dysfunctions in 
IBD (Antonioli et al., 2014a,b). Thus, the appropriate choice of a specific IBD model in 
experimental research represents a fundamental starting point to perform an accurate 
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analysis of novel therapeutic strategies addressing one or more of the multiple pathologic 
mechanisms associated with IBD (Fig.4). The combination of novel researches on animals 
model of IBD and patients would result in a deeper knowledge about innovative factors 
and pathways in IBD, in order to effectively understand the multifaceted etiology of these 
disorders. 
 
 
Figure 4: Schematic representation of main animal models of Inflammatory Bowel Disease, accompanied by 
major mucosal immune functions/therapies that are best addressed using these respective models. 
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CHAPTER 2 
The enteric nervous system and Inflammatory Bowel Disease: 
Role of enteric mediators on bowel dysmotility and inflammation 
 
Gastrointestinal (GI) functions, including secretion, regulation of local blood flow and 
motility are under the control of the enteric nervous system (ENS), a composite neuronal 
network within the gut wall, responsible for a semi-autonomous regulation of GI activity. 
The ENS is extended from the oesophagus to the rectum, and it is organized into two major 
plexi, the submucosal (Meissner's) plexus and the myenteric (Auerbach’s) plexus (Goyal & 
Hirano, 1996) (Fig.5). Each plexus contains neuronal cells and enteric glial cells; neuronal 
cell bodies are clustered in ganglia, with axonal projection connecting the ganglia and 
innervating effectors, including smooth muscle cells, endocrine glands and vasculature. 
The submucosal plexus is deputed to the regulation of GI absorption, secretion and blood 
flow, whilst the Auerbach’s plexus is primarily implicated in the fine modulation of GI 
motility, and it is located between the circular and longitudinal muscle layers of the gut 
wall (Johnson et al., 2012). Interestingly, 2/3 of ENS neurons are hosted in the myenteric 
ganglia, suggesting the great complexity of enteric circuitry modulating GI motility 
(Furness, 1987). Additionally, a mucosal plexus extending to the lamina propria and 
epithelium has been also reported, since ongoing studies provide evidence for a potential 
involvement of the ENS in modulating diverse mucosal functions as well as the function of 
immune cells belonging to the GALT (Rescigno et al., 2008; Genton & Kudsk, 2003).  The 
ENS can autonomously ensure proper GI function through its complex organization 
including sensory neurons (intrinsic primary afferent neurons: IPANs), interneurons and 
motoneurons, realizing functional circuitries capable of generating stereotyped behaviours 
patterns, especially secretory and motor patterns as the peristaltic reflex (Hansen, 2003) 
However, a connection of the ENS with the central nervous system (CNS) is ensured by 
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extrinsic innervation, since both the sympathetic and the parasympathetic system  influence 
the ENS activity (“the brain-gut axis”) (Fig.5): sympathetic noradrenergic fibers inhibiting 
GI activity, and parasympathetic vagal and sacral fibers usually promoting GI function 
(Phillips & Powley, 2007). Also, extrinsic vagal and spinal afferents supply the CNS with 
information about gut discomfort or pain, electrolyte homeostasis and tissue integrity. 
Given its complexity and a number of neuronal cells similar to the brain and the spinal 
cord, the ENS has been classically considered as the “the second brain” (Gershon, 1998). 
Such definition is sustained by the large number of different neurotransmitters (NTs) and 
mediators involved in ENS circuitry, including acetylcholine (ACh), serotonin (5-
hydroxytryptamine: 5-HT), vasoactive intestinal peptide (VIP), tachykinins, calcitonin 
gene related peptide (cGRP), neuropeptide Y (NPY), nitric oxide (NO), pituitary adenylate 
cyclase-activating polypeptide (PACAP), somatostatin, encephalin and purines, as ATP 
and adenosine (Furness, 1994). Research efforts have successfully clarified the role of 
different ENS mediators, identifying for instance NTs released by excitatory motoneurons, 
including ACh and tachykinins, or by inhibitory motoneurons, including VIP, NO, ATP, 
PACAP. In addition, enteric sensory neurons are reported to mainly utilize ACh, 
tachykinins and cGRP. However, even more important is the great series of mediators 
released by interneurons, as ACh, NO, somatostatin, encephalin and many other, capable 
of opportunely modulate the activity of other enteric neurons in order to realize the 
physiologic neural integration required for a coordinated and proficient GI function 
(Bornstein et al., 2004).  
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Figure 5: (Top) Organization of plexi of the Enteric Nervous System within the intestinal wall.                      
(Bottom): Detail of some of the circuitry of the Enteric Nervous System, and its connections with 
sympathetic and parasympathetic systems.  
Abbreviations: 5-HT, 5-hydroxytryptamine; ACh, Acetylcholine; CM, Circular Muscle; LM, Longitudinal 
Muscle; MP, Myenteric Plexus; NE, Norepinephrine; NP, Neuropeptides; SMP, Submucosal Plexus.  
 
 
 
Different studies have reported the pathological changes affecting ENS during IBD, mostly 
resulting from action of inflammatory mediators as cytokines, arachidonic acid-derived 
metabolites and oxygen free radicals (Lomax et al, 2005). Major structural changes in the 
ENS include changes in the plexus architecture, hypertrophy and hyperplasia of the neural 
fibers and alterations of the cell body of neurons and enteric glial cells. Studies conducted 
in patients with CD, UC and control subjects showed that nerve fibers in the ileum and 
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colon appear dilated, empty, sometimes with large vacuoles in the vicinity of the cell 
membrane. These structural abnormalities are related to axonal damage and necrosis 
(Geboes & Collins, 1998). Immunohistochemical studies in patients suffering from Crohn's 
disease revealed an increase of neurons positive for the nitric oxide synthase (NOS) and 
vasoactive intestinal peptide (VIP), primarily suggesting the possibility of disturbed neural 
modulation of smooth muscle relaxation in the inflamed intestine (Geboes & Collins, 
1998). Indeed, novel studies have underlined that structural changes in the ENS during 
IBD are likely accompanied with functional changes, including changes in the electrical 
properties and excitability of enteric neurons and modification in the contribution and role 
of the different enteric mediators constituting the network of the ENS (Mawe, 2015; 
Lakhan & Kirchgessner, 2010). Thus, both structural and functional pathological changes 
in the ENS could be responsible for the reported disturbance in GI motility in IBD patients, 
together with defects in enteric smooth muscle cells (Ohama et al., 2007). However, 
although the aberrant GI motility in IBD could prominently contribute to different major 
symptoms including diarrhoea, weight loss and malnutrition, the consequences of the IBD-
related inflammatory event on GI motility have been currently largely overlooked. Studies 
in IBD patients and animal model of IBD reported that motility pattern is predominantly 
altered towards a diarrheic state, with a pathologic increase in stool frequency. In the 
colon, suppression of colonic Rhythmic Phasic Contractions (RPCs) and increased 
frequency of Giant Migrating Contractions (GMCs) have been reported (Sarna, 2010). 
Overall, a reduced colonic contractility and the decrease in spontaneous contractions seems 
mainly result in a diminished resistance to luminal transit, which, in combination with 
altered secretory activity, could thus lead to the observed diarroic condition. Of 
importance, dysmotility in IBD is not limited to the distal part of the GI tract; indeed, small 
intestinal contractility seems to be enhanced in human CD (Vermillion et al., 1993), whilst 
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defective gastric emptying was also observed (Kristinsson et al., 2007) (Table 1). Thus, it 
is believed that inflammation could modulate the whole ENS circuitry, inducing pathologic 
GI motor behaviour pattern along the entire GI tract. Pathological changes in motility thus 
exacerbate IBD by promoting diarrhea and generally impairing digestive function, likely 
leading to reduced nutrients absorption. Intriguingly, motility disturbance have been 
reported even during clinical remission in IBD, suggesting the existence of pathological 
long-lasting changes in bowel patterns (Bassotti et al., 2014).  
Recent studies underlined the effective possibility that motility disturbance could derive 
from the action of different cytokines, major mediator of inflammation, on the gut 
neuromuscular apparatus. As an example, in the 2,4,6-trinitrobenzenesulfonic acid (TNBS) 
murine model of IBD, decreased contractility was attributable to the action of different 
cytokines, such as IL-1β, TNF-α and IL-12 (Kinoshita et al., 2006; Kisoyue et al., 2006).  
However, as aforementioned, accumulating evidence pointed out the effective importance 
of changes in expression of enteric mediators and neurotransmitters, as well as of their 
specific receptors, in the IBD-associated dysmotility. An increased number of serotonin (5-
HT)-producing enterochromaffin cells (ECCs) has been revealed in animal models of IBD 
and IBD patients (Oshima et al., 1999; El-Salhy et al., 1997); 5-HT is strongly involved in 
the modulation of vagal afferent signaling stimulating motor reflexes, as well as within the 
circuitry of the ENS as trigger of intestinal peristalsis (Grider et al., 1996). Thus, changes 
in 5-HT levels in IBD could be associated with the disturbance in GI motility. Although 
increased 5-HT signaling in IBD would be expected to promote motility, experimental 
evidence have shown that increased 5-HT could paradoxically result in inhibition of 
propulsive activity, as a consequence of receptor desensitization (Linden et al., 2003).  
In addition, increased levels of the enteric mediator substance P (SP), belonging to the 
family of tachykinins peptides and largely involved in the regulation of excitatory 
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signaling in the ENS, have been reported in the colonic tissues of IBD patients, 
accompanied by an increased expression of its specific receptor NK-1 (Renzi et al., 2000). 
Actually, a shift from a mainly cholinergic to a SP innervation in IBD has been observed, 
and the density of SP nerve fibers seem to correlate with the severity of IBD (Bernstein et 
al., 1993). Apart from the potential misbalanced neural excitatory signaling in the ENS due 
to the increased contribution of SP, a plethora of studies reported that SP is also able to 
stimulate cytokines production from endothelial cells, macrophages and mast cells 
(O’Connor et al., 2004), thus potentially contributing to the sustainment of inflammation 
and cytokine-induced motility dysfunction. Another series of researches underlined the 
increased Vasoactive Intestinal Peptide (VIP) concentration in colonic biopsies from CD 
patients as well as in colonic tissues isolated from animal model of IBD (Todorovic et al., 
1996), as guinea-pig TNBS model (Linden et al., 2005) and dextran sulfate sodium (DSS) 
model in rat (Kishimoto et al., 1992). An increased VIP innervation was also observed 
(Bishop et al., 1980). VIP is an enteric mediator involved in the modulation of secretory 
responses and inhibitory motor neurons, mediating relaxation of intestinal smooth muscle 
cells together with other mediators as NO and PACAP. Intriguingly, the prior observation 
of augmented VIP-containing nerves in IBD patients was later accompanied by the 
demonstration of increased nitric oxide synthase and PACAP immunoreactivity (Belai et 
al., 1997), suggesting the possibility of an overall pathologic potentiation of inhibitory 
signaling in the ENS during inflammation. Accordingly, an increased non adrenergic non 
cholinergic innervation associated with impaired contractility have been proposed as a 
major responsible for GI dysmotility in UC (Tomita et al., 1998). Apart from this and other 
pioneer observations, the exact and specific contribution of the large number of enteric 
mediators in the physiopathology of defective intestinal motor activity is still a matter of 
investigation, and novel researches are needed to unravel the precise mechanisms 
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underlying the dysmotility, even in a translational perspective aiming to identify specific 
treatment for the IBD-associated gut motility dysfunction. Indeed, most of current 
therapeutic strategies for dysmotility in IBD have been extrapolated from general treatment 
of dysmotility in functional gastrointestinal disorders, overlooking the development of a 
therapy specifically targeting the effective pathways involved in the dysfunction.  
 
Table 1. Intestinal motility disturbances described in patients with IBD 
 
 
LOCAL 
 
Colon:  
 Decreased contractility (Snape et al., 1991)  
 Reduction in spontaneous contractions (Boyer et al., 1997) 
 Variation in colonic transit (Reddy et al., 1991) 
 
Small intestine:  
 Enhanced contractility (Vermillion et al., 1993) 
 Increased orocaecal transit time (Tursi et al., 2003) 
 
 
 
REMOTE 
 
 Decreased gastric emptying in CD (Kohno et al., 2007) 
 Gastroparesis in patients with inactive CD (Kristinsson et al., 2007) 
  
Abbreviations: CD, Crohn’s Disease; IBD, Inflammatory Bowel Disease.  
 
However, the involvement of enteric mediators in the physiopathology of IBD could not be 
limited to the changes in bowel motor patterns; indeed, a series of recent studies have 
underlined the concept of the ENS as a source of a large amount of compounds potentially 
acting on immune cells and thus involved in the control of both physiologic immune 
response and GI inflammation, focusing their attention on the importance of the 
“neuroimmune dialogue” between the ENS and the intestinal mucosal immune system 
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(Genton et al., 2003). Previous studies identified neural mediators as a novel category of 
compounds capable of regulating immunity (Pacheco et al., 2012) (Fig.6). Immune cells 
possess different receptors for neurotransmitters, functionally coupled to the modulation of 
classic inflammatory processes including cytokine production, proliferation, chemotaxis, 
phagocytosis (Holzmann et al., 2012). As an example, dopamine (DA) has been reported to 
act both on dendritic cells (DCs) and T cells, with a pro- or anti-inflammatory role 
depending on its concentration and receptor subtype expressed (Pacheco et al., 2014). 
Also, a cholinergic anti-inflammatory pathway (CAIP) has been widely explored: in an 
event of uncontrolled inflammation, elevated levels of pro-inflammatory cytokines 
detected in the brain trigger a vagal-mediated reflex, resulting in an increase of ACh 
release in the spleen. In turn, ACh dampens cytokine production from splenic macrophages 
via activation of nicotinic α7 receptors (Tracey et al. 2007), preventing the pathologic 
consequences of uncontrolled inflammation.  
 
 
Figure 6: Novel view regarding common regulation of immune cells and neuronal cells activity by 
neurotransmitters and cytokines . Neurotransmitter-mediated regulation of  immune cells (sx) and cytokine-
mediated regulation of neuronal and glial cells (dx). Abbreviations: DC, Dendritic Cell.  
(Adapted from Pacheco et al., 2012) 
 
In 2014, Matteoli et al. extended the concept of CAIP, demonstrating the possibility of a 
vagal-dependent dampening of intestinal inflammation via an ENS-mediated control of 
enteric macrophages function. Indeed, the network of contacts between the ENS and the 
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intestinal immune cells constituting the GALT (Rescigno et al., 2008) effectively supports 
the existence of mechanisms of neuroimmune modulation even in the gut, suggesting the 
possibility of an effective functional cooperation between these two systems. In this 
context, a lot of studies reported major pro- or anti-inflammatory effects of enteric 
neuropeptides, as SP and neuropeptide Y (NPY) (Margolis & Gershon, 2009); SP induces 
cytokine production from immune cells via activation of NK-1 receptors (Derocq et al., 
1996), and, accordingly, NK-1 antagonists were found to ameliorate inflammation in IBD 
animal model (Ursino et al., 2009). NPY could have a pro-inflammatory role modulating 
immune cells activity, and accordingly NPY knockout mice have been found to be resistant 
to DSS-induced colitis (Chandrasekharan et al., 2008). Also, a complex modulatory role of 
enteric purinergic mediators in the intestinal inflammatory event has been described 
(Antonioli et al., 2008), and serotonin deficiency results in amelioration of experimental 
gut inflammation (Ghia et al., 2009). Hence,  unravelling the specific roles of the different 
ENS mediators on immune cells could open the way to a novel strategy for the treatment of 
GI inflammatory states, targeting the “neuro-immune dialogue” in the gut. 
Overall, it is becoming increasingly clear that a more accurate characterization of the role 
of the ENS and enteric mediators could result in important novel findings clarifying the 
complex physiopathology of IBD, as well as in providing a major scientific rationale for 
improving the current therapeutic strategy for IBD, both targeting the inflammatory event 
and the GI mechanical dysfunction.  
 
 
 
 
 
 
29 
 
CHAPTER 3 
 
 
Angiotensin II and the renin-angiotensin system (RAS) 
 
Angiotensin II (Ang II) represents the major effector of the renin-angiotensin system 
(RAS), the principal modulatory system involved in the fine regulation of systemic blood 
pressure, as well as homeostasis of body fluids and electrolytes (Atlas, 2007) (Fig.7). 
Stimuli as low pressure detected by baroreceptors present in the juxtaglomerular cells of 
the renal arterioles, but also hyponatremia detected by cells of the macula densa in the 
distal tubule, trigger the initiation of the classic RAS pathway, via the first event of 
production and blood release of the enzyme renin by the renal juxtaglomerular apparatus. 
In turn, renin proteolyzes the angiotensigen, produced and released into the bloodstream by 
the liver. The product of this reaction is angiotensin I, a decapeptide, that by the action of 
the angiotensin-converting enzyme (ACE) loses two amino acids giving rise to the 
octapeptide Angiotensin II (Ang II). Ang II causes vasoconstriction and regulates blood 
pressure both directly, by modulating the absorption of water and sodium in the kidneys, 
and indirectly by stimulating the production and release of aldosterone from the adrenal 
glands, or centrally stimulating thirst pathways (Lavoie & Sigmund, 2003).  
Apart from the regulation of blood pressure and water and electrolytes absorption, classic 
RAS has been reported to be involved in cardiac hypertrophy and in inflammation and 
fibrosis (Garg et al., 2012), especially through activation of the angiotensin type 1 
receptors (AT1Rs). In recent years, different studies provided evidence for the final 
identification of two receptor subtypes for Ang II, namely the AT1Rs and the AT2Rs, 
whose functions appear to be antagonistic in most cases, as well as the characterization of 
an alternative RAS, where a counterpart of the ACE, called ACE-2, lead to the production 
of a different peptidic products, namely the Ang (1-7)  and Ang (1-9) (Speth & Giese, 
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2013). Recent current investigations have showed that Angiotensin (1-7) effects include 
promotion of the release of NO and consequently vasodilation, inhibition of cell growt in 
the vessel wall, as well as anti-inflammatory, anti-fibrotic and neuroregenerative actions 
(Santos et al., 2000).   
 
 
Figure 7: Schematic representation of the Renin-Angiotensin system (RAS). 
Abbreviation: BP, Blood Pressure 
 
 
Angiotensin II receptors 
Angiotensin II carried out its functions by the activation of two subtypes of receptors, the 
AT1 and AT2 receptors (AT1Rs and AT2Rs) (De Gasparo et al., 2000) (Fig.8), which are 
seven transmembrane, G protein-coupled receptors (GPCR), with a sequence similarity of 
30%. Most species express a single autosomal gene AT1, while rodents express two genes 
that are named AT1A and AT1B. AT1Rs are predominantly coupled to protein Gq/11, and 
they mediate signal transduction through the phospholipases A, C and D, the inositol 
phosphates, calcium channels, and a variety of serine/threonine and tyrosine kinases. 
AT2Rs are higly expressed during fetal development, while they are much less abundant in 
 
31 
 
adult tissues, although their upregulation has been observed in different pathological 
conditions. AT2Rs mediate signal transduction through serine and tyrosine phosphatases, 
phospholipase A2, nitric oxide and cyclic GMP (De Gasparo et al., 2000). 
 
 AT1 receptors (AT1Rs) 
The AT1Rs mediate most of classic responses to Ang II, as vasoconstriction, synthesis and 
release of aldosterone, and centrally induction of thirst (Speth & Giese, 2013). AT1R 
protein is constituted of 359 aminoacids and encoded by a single gene localized in 
chromosome 3. AT1Rs belong to the superfamily of GPCRs, thus the binding of Ang II 
induces a conformational change promoting the interaction with the G protein, which in 
turn modulate different effector systems. These latter include phospholipase C, D and A2, 
adenylate cyclase and ion channels. Over time, the AT1 receptor undergoes desensitization 
and regulation via internalization (Thomas et al., 1996). Responses induced by activation 
of the AT1Rs include smooth muscle contraction, secretion of aldosterone, neuronal 
activation, neurosecretion, ion transport (De Gasparo et al., 2000). In addition, these 
receptors could also regulate gene transcription and the expression of proteins that control 
the growth and cell proliferation in target tissues of Ang II. However, a chronic increase in 
levels of Ang II could also result in fibrosis and other pathophysiological changes in target 
organs possessing the AT1Rs (Robert et al., 1999). Intriguingly, activation of  AT1Rs by 
Ang II could also induce pro-inflammatory pathways; stimulation of the AT1 receptor 
induces maturation of dendritic cells (DCs) and enhances the production of 
chemokines/cytokines, such as IL-6, IL-1α, and C-reactive protein (De Gasparo et al., 
2000); increased expression of Toll-like receptor 4 (TLR-4) and reactive oxygen species 
(ROS) was also observed (Speth & Giese, 2013).  
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 AT2 receptors (AT2Rs) 
AT2 receptor is a GPCR displaying an homology of 30% with the aminoacid sequence of 
the AT1R. AT2R consists of 363 aa and its gene is located on the X chromosome in 
humans, rats and mice. Its expression is high and ubiquitous in the fetus, then it starts to 
decrease after birth, even completely disappearing in some tissue as the skin. In other 
tissues, such as the adrenal gland and the heart, the AT2R level decreases to a certain low 
but still detectable point, and then persists for the rest of life (Speth & Giese, 2013). The 
characterization of the precise functions of this receptor are still ongoing, but it has been 
shown to mainly counteract the actions mediated  by the AT1Rs.  Indeed, activation of 
AT2R is vasodilatory, antiproliferative, pro-apoptotic and pro-differentiation, 
counteracting the vasoconstrictor, anti-proliferative and anti-apoptotic actions mediated by 
the AT1R (Fig. 6) (Csikos et al., 1998). AT2Rs activity is prominent in cells not 
undergoing growth, and AT2 receptor is not subject to desensitization and internalization, 
accordingly with its likely role of maintaining differentiated cells into a state of quiescence 
(Unger, 1999). As an example, activation of AT2Rs on neonatal hypothalamic neurons 
induces the serine/threonine phosphatase PP2A pathway, in turn inactivating Mitogen-
activated protein kinase (MAPK) (Huang et al., 1999). This event leads to suppression of 
cell growth and induction of differentiation. The distribution of the AT2 receptors in 
various organs, such as the brain, heart, vascular tissue, adrenal, kidney, skin or intestine 
suggests a physiological role of AT2Rs in various body districts, but a plethora of studies 
also underlined its effective involvement in pathophysiological processes (De Gasparo et 
al., 2000), as inflammation and fibrosis, suggesting the necessity of increasing research to 
establish the AT2Rs as possible novel therapeutic targets in different disorders.  
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Figure 8: Major effects induced by activation of AT1 and AT2 receptors by Angiotensin II  
 
The local RAS in the gastrointestinal tract:  
physiological and pathological roles 
 
Differently from the prior assumption of the RAS as a sole endocrine system, generating 
peptides and enzymes released into the blood stream which then act on the target organs, 
recent studies have progressively demonstrated that most organs including the brain, 
kidneys, heart, liver, pancreas, reproductive organs, skin and intestine, constitutively 
express all components of the RAS, which could thus constitute local systems involved in 
tissue homeostasis with paracrine/autocrine function. As an example, the heart expresses 
renin, ACE, AT1R and AT2R, modulating myocytes proliferation (Urata et al., 1990) and 
the brain expresses renin, angiotensinogen, Ang II, Ang (1-7), AT1R, AT2R, locally 
regulating blood pressure, fluid and electrolyte balance, the thirst, the blood-brain barrier 
and neuronal pathways of learning and memory (Ganten et al., 1971). Even more relevant 
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could be the contribution of a local RAS within the GI tract; indeed, components of RAS 
including renin, angiotensinogen, ACE, AT1 and AT2 receptors have been identified in the 
intestine of animal model and humans (Hirasawa et al. 2002; Mastropaolo et al., 2015). In 
the small intestine, RAS seems to be involved in various processes as bicarbonate 
secretion, absorption of sodium, water, glucose and peptides, as well as in the regulation of 
motility (Garg et al., 2012). Indeed, Ang II induces contractile responses of longitudinal 
muscle of guinea-pig small intestine, via activation of neural AT1Rs, modulating release of 
ACh and substance P, and AT1R located on enteric smooth muscle cells (Hawcock & 
Barnes 1993). Subsequently, human studies also confirmed the role of AT1Rs in Ang II-
induced contractions in the small intestine (Ewert et al., 2006). Regarding the colon, 
previous studies in our laboratory have demonstrated the presence of RAS components in 
mice and human colon, including renin, angiotensinogen, ACE, AT1Rs and AT2Rs 
(Mastropaolo et al., 2015). Ang II induced contractions of the colonic smooth muscle 
acting on AT1 receptors; interestingly, an interaction of Ang II with the tachykinergic 
signaling has been identified both in mice and humans. However, in mice, Ang II induces 
release of SP, in turn causing release of ACh through activation of neural NK-1 receptors; 
ACh is thus the final mediator causing smooth muscle contraction. On the other hand, in 
human colon, Ang II via the AT1Rs mediates the release of Neurokinin A (NKA) causing 
smooth muscle contraction acting on NK-2 receptors on smooth muscle cells. Although the 
expression of AT2 receptors has been reported in the GI tract of different animal species 
(Fändriks, 2010), Ang II-induced effect on GI motility seems to be dependent mainly on 
the activation of AT1Rs, suggesting that novel researches are needed to reveal the possible 
contribution of AT2 receptors in physiological or pathological conditions. Indeed, the local 
RAS in the small and large intestine is likely to play a physiological role within the 
neuronal network governing motility, but pathological changes of RAS signaling in the GI 
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tract, including changes in receptors expression, could influence GI motor disorders as well 
as motor activity in inflammatory conditions, as IBD.  
In line with this hypothesis, a series of recent studies has also pointed out the possible 
involvement of RAS system in GI inflammation, especially in IBD. Mucosal levels of Ang 
II are higher specifically in CD patients (Jaszewski et al., 1990), and increased 
concentrations of Ang (1-7) and ACE2 have been also reported in IBD patients (Garg et 
al., 2014), suggesting the involvement of both the classic and alternative RAS in 
inflammation. Experimental studies revealed that inhibition of ACE or antagonists of 
angiotensin receptors (especially AT1Rs blockers) ameliorate inflammatory damages in 
murine colitis, reducing production of pro-inflammatory cytokines and increasing the 
levels of anti-inflammatory cytokines as IL-10 (Garg et al., 2012). Also, AT1a receptor-
deficient mice displayed less severe experimental colitis than wild-type mice (Katada et al.. 
2008). Thus, a in-depth examination of changes in classic and alternative RAS components 
could lead to the definition of RAS as a novel modulator of the inflammatory event, and 
thus a potential novel therapeutic target in IBD for the treatment of both inflammation and 
IBD-related GI motor dysfunction.  
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3.1 
Different role for Angiotensin II receptors in the modulation of colonic 
motility in a murine model of Inflammatory Bowel Disease 
 
 
3.1.1 Aim 
 
Since novel investigations are needed to effectively disclose the possible of enteric RAS 
system in physiological and pathological conditions, in order to establish its potential as 
new possible target for treatment of IBD-associated GI motor dysfunction and 
inflammation, the aim of this study was to analyse and compare, in vitro, the possible 
effects of Ang II on colonic motor activity in control rats and in animal subjected to 
treatment with 2,4-dinitrofluorobenzenesulfonic acid (DNBS), as model for IBD. In 
particular, we characterize the different inflammatory markers in the DNBS model, the 
contractile activity, the effects of Ang II, the receptor subtypes involved, as well as their 
possible role in the dysmotility observed  in DNBS-treated animals versus controls. 
 
3.1.2 Materials & Methods 
Animals  
Sixteen female Wistar rats (weighing 200-300 g), obtained from Charles River 
Laboratories (Calco-Lecco, Italy) were used in the experiments. The animals were kept in 
the animal facility of the Department of Biological, Chemical and Pharmaceutical Sciences 
and Technologies (STEBICEF), in a controlled environment (room temperature (22 ± 2°C) 
and humidity (60%) and 12h:12h day-night cycle), and fed with standard pellets and water 
ad libitum throughout the study. Animals were allowed to acclimatize to housing 
conditions for 1 week prior to experimentation. All experimental procedures were 
approved by Ministero della Sanità (Rome, Italy). 
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Colitis induction 
Animals were randomly assigned to the control group and the colitis group (8 animals 
each). For the experimental induction of colitis, animals were fasted overnight and the 
following day, under light anaesthesia with isofluorane, a solution of 30 mg of 2,4-
dinitrobenzensulfonic acid (DNBS) in 50% ethanol, for a total volume of 0.25 mL, was 
intracolonically instilled in each animal using a 8 cm plastic catheter (PE90). In control 
experiments, animals received 0.25 mL of saline solution (0.9% NaCl). The rats were 
sacrificed on the sixth day after the treatment with DNBS or saline.  
 
Evaluation of inflammatory markers: 
1) Disease Activity Index (DAI) 
In the 6 days following treatment the weight and the fecal consistency of each animals 
were evaluated daily. These parameters were collected to assess a numerical index, the 
Disease Activity Index (DAI), as a combination of a Weight Loss % Score and Stool 
Consistency Score, in order to establish the severity of ongoing inflammation. The scores 
have been calculated daily according to the tables below: 
 
 
 
 
 
 
 
 
Weight loss % Score 
0: < 1% 
1: 1-5% 
2: 5-10% 
3: 10-15% 
                4: >15% 
Stool Consistency Score 
0: normal 
2: loose stool 
4: diarrhea 
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Weight loss was calculated as the percent difference between the original body weight 
(equated as 100%) and the daily body weight. The final daily DAI Score resulted as a 
mean of the Weight loss % Score and the Stool consistency Score. 
 
2) Analysis of macroscopic inflammatory damage 
On the 6th day after the treatment with DNBS or saline, the animal was sacrificed and the 
colon removed, opened longitudinally and washed with Krebs solution, removing all the 
intraluminal contents. The weight and the length of the colon were registered, in order to 
calculate the weight/length ratio as indicator of colonic edema.  
Then, macroscopic damage was scored as following:  
 Presence and extension of tissue damage in the distal colon: 0, 1, 2, 3, 4, 5, 6 
(normal aspect of mucosa, localised hyperemia with no ulcers, ulceration without 
hyperemia/bowel wall thickening, ulceration with hyperemia/bowel wall thickening 
at 1 site, two or more sites of ulceration with hyperemia/bowel wall thickening, 
major damage (necrosis) extended more than 1cm, major damage (necrosis) 
extended over 2 cm. If the damaged area covered more than 2 cm, the score was 
increased by 1 for each additional cm involved); 
 Presence of adhesions between the colon and other organs: 0, 1, 2 (none, minor, 
major); 
 Fecal consistency: 0, 1 (normal, diarrhea); 
 Maximal thickness of the colonic wall (in mm); 
The cumulative Score of the different parameters represents a numerical index determining 
the severity of macroscopic damage (Macroscopic Damage Score). 
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3) Analysis of microscopic inflammatory damage 
A representative section of colon from each animal was fixed in 4% formaldehyde for 24h 
and embedded in paraffin for hematoxylin-eosin staining. Sections were observed under an 
optical microscope to evaluate and quantify the extent of inflammatory pathological 
changes, as following:  
 Loss of mucosal architecture: 0, 1, 2, 3 (normal, mild, moderate, severe); 
 Cell Infiltration: 0, 1, 2, 3 (absent, mild, moderate, severe); 
 Muscle thickening: 0, 1, 2, 3 (absent, mild, moderate, severe); 
 Presence of crypt abscesses: 0, 1 (absent, present); 
 Depletion of globets cells: 0, 1 (absent, present); 
The total sum of the scores represents a numerical index determining the severity of 
microscopic damage (Microscopic Damage Score). 
 
4) Myeloperoxidase Assay 
Myeloperoxidase (MPO) is an enzyme able to detoxify the cells from reactive oxygen 
species (ROS), present primarily in neutrophils and other cells of myeloid origin, and 
commonly used as a quantitative marker for establishing the degree of severity infiltration 
of immune cells during intestinal inflammation (Krawisz et al., 1984).  
For each animal, a sample of tissue (around 100 mg) was removed from the area of major 
damage, snap frozen in liquid nitrogen and assayed within seven days using a the method 
described by Boughton-Smith et al. (1988). Before starting the MPO assay, samples were 
placed on ice for 15 minutes for unfreezing. The samples were then constantly kept in ice 
for the entire duration of the protocol, reported below: 
1) Addition of detergent hexadecyl-trimethylammonium bromide (HTAB; 1mL/50 mg of 
tissue); 
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2) Homogenization of the tissue by Polytron at medium speed for about 20 s 
3) Centrifugation at 6000g for 10 min at 4 °C 
4) Collection of 35 μL of supernatant and loading of each sample in a cuvette with the 
addition of 1mL of solution of o-Dianisidine dihydrochloride and 250 μL of a solution of 
30% hydrogen peroxide (H2O2). 
5) Reading of the absorbance at the spectrometer λ = 450 nm (3 readings at 30-second 
intervals: 0-30-60 s). 
Through a statistical software (GraphPad Prism version 4:00 for Windows, GraphPad 
Software, San Diego, California USA), a graph of the absorbance (A) as a function of time 
was designed, in order to extract the value Slope (Z), representing the change in 
absorbance over time. Considering the change in absorbance of 1.13*10
-2
 associated with 1 
μmole of H2O2, total units of MPO will be equal to Z/1.13*10
-2
. Since the ratio 
tissue/buffer is equal to 50 mg/ mL, then in 35 μL of supernatant there are 1.75 mg of 
tissue; consequently to obtain units MPO/mg, the previous value was divided by 1.75. 
Hence, the MPO was finally expressed in units MPO per mg of tissue, where one unit of 
MPO corresponds to the activity required to degrade a 1 μmole of H2O2 in one minute at 
room temperature. 
 
Evaluation of the mechanical activity of colonic longitudinal muscle strips in vitro: 
Longitudinal smooth muscle strips (10 mm in length) from the distal colon of control and 
DNBS-treated animals were prepared and suspended in the four channels of a vertical 
organ bath, each containing 10 mL of Krebs solution, oxygenated (95% O2 and 5% CO2) 
and maintained at a constant temperature of 37°C (Fig.9). The distal end of the strips was 
fastened to a small glass hook located inside of each channel, whilst the proximal end was 
connected, by means of a silk thread, to the hook of a isometric force transducer (FORT 
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125, Ugo Basile Biological Research Apparatus, Comerio VA, Italy), which allowed to 
supply as output, in proportion to the force applied on entry, a linear voltage with very low 
deflections. The mechanical activity was digitized by an A/D converter, displayed and 
recorded on a personal computer, using the PowerLab /400 system (Ugo Basile, Biological 
Research Apparatus, Italy), and finally analyzed using the program CHART4. The 
preparations were subjected to an initial tension of 500 mg and then left to equilibrate for 
at least 30 min, until stable spontaneous mechanical activity was observed.   
Preparations from controls and DNBS rats were challenged with 10 μM carbachol (CCh) 
until stable responses were obtained. Increasing concentrations of Ang II were applied in a 
non-cumulative manner for approximately 5 min at regular 90 min intervals, to obtain 
concentration-response curves. In a second series of experiments, the effects of Losartan, 
selective AT1 receptor antagonist, and PD123319, AT2 receptor antagonist, were tested. In 
addition, tetrodotoxin (TTX), blocker of neural Na
+
 voltage-gated ion channels, N
G
-Nitro-
L-arginine (L-NNA), an inhibitor of neural/endothelial nitric oxide synthase 
(nNOS/eNOS), or 1400W, an inhibitor of inducible NOS (iNOS), were tested on the 
response induced by a sub-maximal concentration of Ang II. Antagonists were left in 
contact with the tissue for at least 20 minutes before challenging the preparation with Ang 
II. Concentrations of the drugs used were determined from previous experiments 
(Mastropaolo et. al. 2013, 2015) and from literature. 
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Figure 9: Organ bath system (top) and particular of an individual channel (bottom) 
 
 
Solutions and drugs 
Krebs solution consisted of (mM): NaCl=119; KCl=4.5; MgSO4 = 2.5; NaHCO3 = 25; 
KH2PO4 = 1.2; CaCl2 = 2.5; and glucose = 11.1. Drugs used were: N-([3-
(Aminomethyl)phenyl]methyl)ethanimidamide dihydrochloride (1400W), carbamylcholine 
chloride (carbachol, CCh), 2,4-Dinitrobenzenesulfonic acid (DNBS), isoproterenol (Iso), 
and Tetrodotoxin  from Sigma-Aldrich Inc. (St Louis, MO, USA). Angiotensin II, 1-[[4-
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(Dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H 
imidazo[4,5-c] pyridine-6-carboxylic acid ditrifluoroacetate (PD123319), 2-Butyl-4-
chloro-1-[[2′-(1Htetrazol-5-yl)-[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol 
potassium salt (Losartan) and N
G
-Nitro-L-arginine (L-NNA) from Tocris Bioscience 
(Bristol, UK). All drugs were dissolved in distilled water, except otherwise stated. 
Working solutions were then dissolved in Krebs solution. 
 
Data analysis and statistical tests 
All data are presented as means ± SEM: ‘n’ indicates the number of animals. Contractile 
responses induced by Ang II were reported as a percentage of the effect induced by 10 μM 
Carbachol (CCh). Ang II responses were fitted to sigmoid curves (Prism 4.0, Graph-PAD, 
San Diego, CA, USA), and EC50 values with 95% confidence limits (CLs) were 
determined.  
Statistically significant differences were calculated by Student’s t-test or by analysis of 
variance followed by Bonferroni’s test, as appropriate. A p-value < 0.05 was considered 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
44 
 
3.1.3 Results 
Characterization of inflammatory markers in the DNBS rat model of IBD 
1) Disease Activity Index 
Animals subjected to treatment with DNBS showed in the following 6 days a progressive 
weight loss (Fig. 10) accompanied by diarroic condition. At day 6 after DNBS injection, 
Weight loss % Score and Stool consistency Score were 2.25 ± 0.8 and 3,5 ± 0.3, 
respectively (n = 8), resulting in a significant Disease Activity Index (DAI mean: 2.87 ± 
0.2, n = 8, day 6 after DNBS, p<0.05 compared to controls) (Table 2). Control animals 
displayed no weight loss (Fig. 10) or changes in stool consistency. 
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Figure 10: Body weight loss monitored during the days after saline (control animals, n=8) or DNBS 
injection (n=8), expressed as a percentage of body weight on day 0.  Data are expressed as Mean ± SEM.  
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   DAI SCORE 
 (DAY 6 ) 
CONTROLS 
(N=8) 
 0 ± 0   
DNBS 
(N=8) 
 2.87 ± 0.2*   
Table 2: Disease Activity Index in saline and DNBS-treated animals at 6th day after treatment.                         
Mean ± SEM. *p<0.05 
 
 
2) Assessment of macroscopic inflammatory damage 
On the 6th day after the treatment with DNBS, the distal colon appeared dilated, thickened, 
highly vascularized and it generally presented an area of major damage with obvious 
ulcerations or necrotic tissue (Fig.11a,b). Diffuse adhesions of the colon with other organs 
were also observed. No evident tissue damages, thickening of colonic wall, adhesions or 
other obvious pathological signs were observed in saline-treated animals (Fig.11c).  
 
 
Figure 11. (a) 
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Figure 11. (b) 
 
 
Figure 11. (c) 
 
Figure 11: Macroscopic appearance of colon from a DNBS-treated animal (a) - (b) or saline-treated animal 
(c).  
 
 
Colon weight/length ratio significantly increased in the DNBS-treated animals compared to 
controls, indicating significant tissue edema (mean 0,12±0,01 in controls vs 0,26 ±0,02 in 
DNBS animals, p<0.05) (Fig.12).  
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Figure 12: Colon weight/Length ratio in colitis versus control animals, expressed Mean ± SEM. *p<0.05 
 
 
Evaluation of macroscopic damage in DNBS-treated animals results in a mean 
Macroscopic Damage Score of 11.3 ± 0.4 (n = 8, day 6 after DNBS) (Table 3). 
   MACROSCOPIC DAMAGE 
SCORE 
CONTROLS 
(N=8) 
 0 ± 0   
DNBS 
(N=8) 
 11.3 ± 0.43*   
Table 3: Macroscopic Damage Score in colitis versus control animals, expressed Mean ± SEM. 
*p<0.05  
 
 
3) Evaluation of microscopic inflammatory damage 
Histological examination showed in the samples of the colon from the DNBS group 
serious pathological changes characterized by infiltration of immune cells in the intestinal 
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wall, moderate to severe loss of mucosal architecture, depleted globet cells and edema 
(Fig. 13).  
              
Figure 13: Microscopic apperance of colonic tissue in control (sx) versus colitis (dx) animals 
 
 
The evaluation of the microscopic damages results in a mean Microscopic Damage Score 
of 4.6 ± 0.4 (n = 8, day 6 after DNBS) (Table 4). 
   MICROSCOPIC DAMAGE SCORE 
CONTROLS 
(N=8) 
0 ± 0 
DNBS 
(N=8) 
4.6 ± 0.4* 
Table 4: Microscopic Damage Score in colitis versus control animals, expressed. Mean ± SEM. *p<0.05 
 
 
 
4) Levels of Myeloperoxidase (MPO) 
The samples of the colon of animals in the group DNBS showed a significant increase in 
the levels of myeloperoxidase (MPO) compared to control animals, indicating an extensive 
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neutrophilic infiltration caused by the treatment (mean: 30.8 ± 4.1 Units/mg, n = 4, day 6 
after DNBS versus 5.75 ± 1.2 Units/mg, n = 4 in the control animals) (Fig.14). 
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Figure 14: MPO levels in colitis versus control animals, expressed in Units of MPO/mg of tissue.                      
Mean ± SEM. *p<0.05  
 
 
Effect of Angiotensin II on the colonic mechanical activity in controls and                    
DNBS-treated animals 
 
Strips of longitudinal muscle of colon obtained from control rats and DNBS-treated rats, 
once mounted in the channels of the organ bath and after the equilibration time, developed 
a spontaneous contractile activity. However, the mechanical activity of the DNBS strips 
was characterized by contractions with an amplitude significantly lower than of 
preparations obtained from control rats (amplitude: 1073.2 ± 67.7 mg, n = 8 in controls and 
231.1 ± 21.0 mg, n = 8, in DNBS rats; p<0.05) (Fig.15). 
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Figure 15: Original tracing showing the spontaneous mechanical activity of colonic longitudinal muscle 
strips from control and DNBS-treated animals 
 
 
 
In addition, DNBS preparations had a significantly lower contractile and relaxant response, 
respectively to carbachol (CCh; 10 μM), muscarinic cholinergic receptor agonist, and 
Isoproterenol (Iso; 0.1 μM), β2-adrenergic receptor agonist, than control preparations, 
confirming an altered colonic motility in DNBS-treated animals (Fig.16). 
 
Figure 16: Histograms showing the effects of CCh (10 μM) and Iso (0.1 μM) in control (n = 8) and DNBS 
preparations (n = 8) . Data are expressed as mean ± S.E.M. *p < 0.05 when compared to the control. 
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The exogenous administration of Angiotensin II (3-300 nM) caused a concentration-
dependent excitatory effect, increasing the basal tone of the colonic longitudinal muscle of 
both groups of animals (Fig.17). However, the response to Ang II in strips from DNBS rats 
was significantly reduced compared to controls, with a significant rightward shift of the 
dose-response curve (EC50 of 35.8 nM, 95% Cls 9.5-125.6 nM in controls; EC50 of 111.8 
nM 95% Cls 59.4-217.9 μM in DNBS preparations) (Fig. 17-18). 
 
 
Figure 17 : Representative original tracing showing the excitatory effect induced by a submaximal dose of 
Ang II (100 nM) in control and DNBS-treated animals.  
 
 
Figura 18 : Concentration-response curves of Ang II (3 -300 nM) in longitudinal muscle strips from colon of 
control rats and DNBS-treated rats. Data are reported as means ± SEM and expressed in % of the excitatory 
effect induced by carbachol 10 μM. *p<0.05 when the concentration-response curve was compared to that of 
controls.  
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In order to determine the receptors involved in the effects mediated by Ang II, samples 
were pre-treated with the AT1 receptor (AT1R) antagonist, Losartan, and the AT2 receptor 
(AT2R) antagonist, PD123319. Losartan (10 nM) antagonized the excitatory effects 
induced by Ang II in both preparations, shifting the concentration-response curve of Ang II 
to the right (Fig. 17) (controls: EC50 of 77.6 nM, 95% Cls 27.1-223.2 nM, n = 6, in the 
presence of Losartan;  DNBS preparations: EC50 of 110.1 nM, 95% Cls 23.1-530.2 nM, 
n=5, in the presence of Losartan) (Fig.19). In contrast, pretreatment with the AT2 receptor 
antagonist, PD123319 (100 nM), had no effect on the control preparations but it led to a 
significant increase of the Ang II effects in DNBS preparations, increasing the maximum 
response of about 35% (Fig. 19) (EC50 of 29.1 nM, 95% Cls 12.2-70.0 nM, n=5, in 
presence of PD123319). Thus, during inflammation, a recruitment of inhibitory AT2 
receptors would counteract the excitatory effect mediated by AT1 receptor, decreasing the 
response to             Ang II. 
 
Figure 19: Concentration-response curves of Ang II (3-300 nM), alone or in the presence of  Losartan                 
(10 nM; n=5) or PD123319 (100 nM n=5) in preparations from controls (left) or DNBS-treated animals 
(right). The data are reported as means ± S.E.M. and expressed in % excitatory effect induced by carbachol 
10 μM . *p<0.05 when the concentration-response curve was compared to that observed in control conditions 
. 
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In order to determine whether the receptors involved in the Ang II-induced effects were 
localized at the level of enteric neurons and/or at post-junctional level, samples were pre-
treated with tetrodotoxin (TTX), blocker of neural Na
+
 voltage-gated ion channels. TTX   
(1 M) did not alter the excitatory effect induced by a submaximal dose of Ang II (100 
nM) in strips obtained from control rats, while in DNBS preparations it significantly 
increased the contractile response to the same extent of the AT2 receptor antagonist 
(Fig.20). These observations indicate that AT1 receptors mediating Ang II excitatory 
effects are located at post-junctional level in the controls, whilst AT2 receptors,  mediating 
inhibitory effects, seem to be located at pre-junctional level in DNBS preparations. 
Since different evidence pointed out that effects of Ang II following activation of the AT2 
receptors may be likely related to nitric oxide (NO), the effects of Ang II (100 nM) in 
DNBS preparations were tested in presence of L-NNA (10 μM), an inhibitor of 
neural/endothelial nitric oxide synthase (nNOS/eNOS) and 1400W (10 μM), an inhibitor of 
inducible NOS (iNOS). The effect of Ang II was increased in the presence of L-NNA, in a 
manner comparable to that observed in the presence of the AT2 receptor antagonist or 
TTX, while no increase was observed in the presence of 1400W (Fig.20). Co-
administration of PD123319 and L-NNA or TTX did not determine additive effects, 
suggesting that the AT2 receptors would induce neural release of NO from inhibitory 
nerves. 
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Figure 20: Histograms showing the effects of Ang II (100 nM) alone, and in the presence of L-NNA (10 
μM), or TTX (1 μM) in preparations of the colon of control rats and in the presence of L-NNA (10 μM) , 
TTX (1 μM), 1400W (10 μM) or following co-administration of TTX and PD123319 (100 nM) or L-NNA 
and PD 123319 (100 nM) in DNBS rats. Data are mean ± SEM and expressed in % excitatory effect induced 
by carbachol 10 μM. * p <0.05 compared to control. 
 
Lastly, the administration of PD123319 (100 nM) induced per se a 40% increase of the 
amplitude of spontaneous contractions, suggesting a tonic activation and participation of 
AT2 receptors in the modulation of the spontaneous mechanical activity during 
inflammation. Noticeably, administration of PD123319 was able to increase also both the 
contractile and relaxant response respectively to CCh (1 μM ; from 1110 ± 78 mg to 1920 
± 252 mg in presence of PD123319, n=4) and Iso (0.1 M; from 550 mg ± 42 to 835 ± 82 
mg in presence of PD123319, n=4). This would indicate that, in our experimental 
conditions, the tonic activation of AT2 receptors could be partly responsible for 
inflammation-associated motility dysfunction.  
However, treatment with PD123319 was not able to effectively restore the amplitude of 
spontaneous contractions observed in controls, as well as the contractile and relaxant 
response to CCh (1μM) and Iso (Fig.15-16), suggesting that AT2 receptor activation would 
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represent solely one of the multiple mechanisms leading to impaired muscle contractility in 
the course of inflammation. 
 
3.1.4 Discussion and conclusions 
Results from our experiments firstly demonstrated that a tonic activation of AT2 receptors 
on inhibitory neurons, in turn leading to NO release, could contribute to the general 
reduction of muscle contractility in the course of experimental GI inflammation. 
Ang II was able to induce smooth muscle contraction of colonic longitudinal muscle strips 
both in control animals and animal subjected to treatment with DNBS, this latter inducing 
an inflammatory event resembling IBD as demonstrated by the evaluation of different 
inflammatory markers, including clinical signs (weight loss, diarrhea), macroscopic and 
microscopic tissue damages (ulcerations, bowel wall thickening, loss of physiological 
mucosal architecture) and extensive immune infiltrate. However, the effect of Ang II was 
lower in preparations obtained from DNBS-treated animals, suggesting modification in 
Ang II-mediated signaling during experimental inflammation. In control animals, the 
contractile effect of Ang II was dependent on AT1 receptors activation, as pre-treatment 
with Losartan, AT1 receptor antagonist, significantly antagonized Ang II effect, being not 
affected by pre-treatment with PD123319, AT2 receptor antagonist. This is line with our 
previous studies about an exclusive role of AT1 receptors in mediating excitatory effects of 
Ang II in the mice and human colon (Mastropaolo et al., 2013, 2015), as well as with other 
studies addressing AT1 receptors as the major effectors of Ang II-related effects (Speth & 
Giese, 2013).  
In preparation obtained from DNBS-treated animals, the contractile effect of Ang II was 
also antagonized by the AT1 receptor antagonist, Losartan, indicating the involvement of 
AT1 receptors, but, interestingly, pre-treatment with the AT2 receptor antagonist, 
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PD123319, resulted in a significant increase of the amplitude of Ang II-mediated 
contractile effect. This observation suggest that, in experimental inflammation, tonic 
activation of AT2 receptors occurs, causing an inhibitory effect on  Ang II-mediated 
contraction. The presence of AT2 receptors in the colon has been reported in human whole 
thickness preparations as well as specifically on epithelium, crypt, mesenchymal cells 
(Hirasawa et al., 2012; Mastropaolo et al., 2015). However, our previous experiments on 
human sigmoid colon did not reveal any involvement of AT2Rs in the modulation of 
colonic mechanical activity in physiological condition (Mastropaolo et al., 2015); 
accordingly, here we observed that AT2Rs were not involved in Ang II-induced 
contraction in preparation obtained by rats not subjected to experimental inflammation. 
The neural blocker TTX did not influence the Ang II-induced response in control samples 
and in inflamed animals in the presence of the AT2 receptor antagonist, indicating that 
AT1 receptors mediating Ang II excitatory effects are located at post-junctional level in 
both preparation. On the other hand, TTX increased the Ang II-dependent contractile 
response in preparation from inflamed animals to the same exent of the AT2 receptor 
antagonist, suggesting that AT2 receptors mediating inhibitory effects may to be located at 
pre-junctional level..  
Thus, during experimental inflammation the tonic activation of neural AT2 receptors 
would induce inhibitory enteric neuronal signaling ultimately resulting in a reduction of 
Ang II contractile effect. Inhibitory signaling in the ENS is dependent on the action of 
different mediators, including for instance NO, VIP and PACAP (Furness, 1994); since 
NO was already identified as a downstream mediator of AT2 receptor signaling (Israel et 
al., 2000), we investigated the possible interplay between AT2 receptors and nitric oxide 
by using different nitric oxide synthase blockers, including L-NNA (nNOS/eNOS blocker) 
and 1400W (iNOS blocker). L-NNA, but not 1400W, was able to increase Ang II-mediated 
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contraction, at as similar level of PD123319; furthermore, the additive administration of L-
NNA and PD123319 did not induce further increase of Ang II-related contractile effect, 
suggesting that activation of AT2 receptors and nitric oxide signaling could effectively 
constitute two steps of a unique pathway. Moreover, the lack of similar effect of 1400W 
underlined the likely neural source of NO, reinforcing the possibility of activation of AT2 
receptors located on enteric inhibitory nitrergic neurons. Lastly, another major finding of 
our study was that AT2 receptor antagonist PD123319 was able per se to significantly 
increase the amplitude of spontaneous colonic contractions, as well as the contractile and 
relaxant response to the muscarinic agonist carbachol and β2-adrenergic agonist 
Isoproterenol in DNBS-treated animals, but not in controls. This would imply that 
inflammation-induced changes in the enteric microenvironment could include a tonic 
activation of AT2 receptors, in turn involved in a negative modulation of the spontaneous 
mechanical activity. Also, AT2 receptors would induce a general depression of smooth 
muscle contractile properties, changing the sensitivity of enteric smooth muscle both to 
muscarinic and adrenergic activation.  
The observed activation of AT2Rs in the course of experimental colitis represents a crucial 
starting point both for a major comprehension of AT2R role and for the understanding of 
novel pathways associated with bowel inflammation. Indeed, the shift from sole AT1 
receptors activation in physiological condition to AT1/AT2 receptors activation in 
inflammation suggest that the local RAS system in the GI tract undergoes substantial 
modifications. If such changes represent solely an inflammation-induced effect on the RAS 
system or a “defense” mechanism of the ENS to counterbalance inflammatory damages is 
currently difficult to clarify. Plasticity is a well-known powerful property of the ENS 
(Schäfer et al., 2009), capable of opportunely reorganizing enteric circuitry in the attempt 
to preserve physiological GI function and respond to pathological changes in the enteric 
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milieu. As aforementioned, the RAS system in the GI tract seems to be implicated in 
sodium and water reabsorption (Garg et al., 2012), and AT2 receptors activation has been 
reported to stimulate absorption of such nutrients in the rat jejunum (Jin et al., 1998). 
Intriguingly, the mechanism underlying AT2-induced modulation of absorption is believed 
to involve NO production (Schirgi-Degen & Beubler, 1995) as reported in the kidney 
(Siragy & Carey, 1996;1997). Considering that water/electrolyte absorption is impaired in 
GI inflammation, including in IBD patients (Head et al., 1969; Barkas et al. 2013), the 
increase in  AT2 receptors signaling and the consequent increase in NO production could 
represent a compensatory mechanism aiming to maintain adequate absorption during 
inflammation. However, considering the possible whole consequences of AT2 signaling on 
GI functions, in our experiment we revealed that the occurring tonic AT2 receptor 
activation mainly result both in a general impairment of enteric smooth muscle 
contractility and in defective spontaneous phasic contractions, suggesting that the shift 
from AT1 to AT2 receptors contribution in the modulation of colonic motility in the 
contest of inflammation could represent a novel target for the development of specific 
therapy for bowel dysmotility in IBD. Potentiated nitrergic neurotransmission could 
account for Ang II-induced changes in contractility, in accordance with the hypothesis of 
an increase in non adrenergic non cholinergic signaling as a possible cause of UC-
associated colonic motor dysfunction (Tomita et al., 1998). In addition, the disclosed 
increased participation of AT2 receptors in inflammation suggests that novel researches 
addressing the role of AT2 receptors in inflammatory pathways are needed. Indeed, most 
of researches have been currently focused on the potential pro-inflammatory role of AT1 
receptors in IBD, and on the use of AT1 receptor antagonists to ameliorate colitis in animal 
model. However, our data revealed that the understanding of the consequences of increased 
AT2 receptor signaling in the ENS, coupled to the nitrergic signaling, could lead to the 
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definition of novel possible Ang II-induced modulatory pathways on immune activity and 
inflammation, allowing a future depict of the comprehensive involvement of the local RAS 
system in GI inflammation.  
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CHAPTER 4 
 
4.1 GABA: γ-aminobutyric acid  
γ-aminobutyric acid (GABA) is an aminoacid derivate widely considered as the main 
inhibitory neurotransmitter (NT) in the central nervous system (CNS) of mammals, 
responsible, together with glutamate, of finely regulating neuronal excitability, and thus 
involved in numerous CNS functions, as well as in the physiopathology of neurological 
diseases including epilepsy, anxiety disorders, schizophrenia, sleep disorders, drug and 
alcohol addiction (Fagg & Foster, 1983; Watanabe et al., 2002). In the CNS, GABA is 
primarily concentrated in the substantia nigra and globus pallidus, as well as in the 
hypothalamus, the periaqueductal gray matter and hippocampus (Petroff, 2002). The 
Purkinje cells in the cerebellum are also GABAergic neurons utilizing the inhibitory action 
of GABA for the fine control and coordination of complex motor functions (Person & 
Raman, 2012). Apart from its prominent action in the CNS, different studies have 
demonstrated the presence of GABA in different peripheral tissues of mammals, and 
organs such as the pancreas, fallopian tubes, uterus, ovary, testes, kidneys, liver, lungs, 
stomach and intestines (Erdo, 1992), driving research efforts into the investigation of the 
action of this neurotransmitter outside the CNS. 
 
4.2 Synthesis and metabolism 
GABA is synthesized from glutamic acid by the glutamic acid decarboxylase (GAD), 
using piridossalphosphate as cofactor (Rowley et al., 2012). Once released in the synapse, 
GABA can act on specific different ionotropic and metabotropic receptors localized in pre- 
or postsinaptyc nerve terminals, as long as its action is terminated by GABA transporters 
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(GATs) allowing reuptake of GABA in the axon terminals or glial cells. Subsequently, a 
GABA transaminase (GABA-T) converts GABA into a succinic semialdehyde. The amino 
group removed from GABA is transferred from the GABA-T to a molecule of α-
ketoglutarate to form glutamic acid for the production of new GABA. Also, succinic 
semialdehyde can be oxidized by succinic semialdehyde dehydrogenase (SSADH) into 
succinic acid and can then enter the Krebs cycle. 
 
4.3 GABA receptors 
GABA interacts with three types of receptors: GABAA, GABAB and GABAC receptors 
(Bormann, 2000). GABAA and GABAC receptors are ionotropic receptors belonging to the 
family of ligand-gated Cl
-
 channels, and mainly responsible for mediating the fast 
inhibitory activity of GABA. GABA-dependent chloride channel gating is generally 
inhibitory on a neuron by mediating inflow of chloride anions, in turn hyperpolarizing the 
neuronal membrane; however, under conditions of high intracellular chloride, as reported 
both in immature neurons and in enteric neurons, GABA-related outflow of chloride 
anions occur, inducing depolarization of the membrane potential (Xue et al., 2009; Liu et 
al., 2013). Such depolarizing action of GABA has been demonstrated as an important 
mechanism in brain development, as well as in the modulation of gastrointestinal functions 
(Perrot-Sinal et al., 2003; Krantis, 2000). GABAB receptors are heterodimeric 
metabotropic G protein-coupled receptors (GPCRs), negatively acting on presynaptic 
voltage-activated Ca
2+
channels and positively acting on postsynaptic inwardly rectifying 
K
+ 
channels, classically mediating the long-term inhibitory action of GABA (Bormann, 
2000).  
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4.3.1 GABAA receptors 
 Structure  
GABAA receptors are pentameric receptors composed of a combination of five subunits 
constituting a chloride channel (Sigel & Steinmann, 2012) (Fig.21). Each GABAA receptor 
subunit is composed of a extracellular N-terminal domain and four membrane-spanning 
domains (M1-M4), followed by a short extracellular C-terminal domain. A long 
intracellular loop between M3 and M4 is believed to be a possible a target for protein 
kinases as well as for anchoring to the cytoskeleton. GABAA receptor subunits have been 
classified into eight classes, including α, β, γ, δ, ε, θ, π and ρ; moreover, several isoforms 
codified by distinct genes have been reported: α (1-6), β (1-4), γ (1-3), ρ (1-3) (Barnard et 
al., 1998). The aminoacid homology between the different classes is about 30-40%, 
suggesting their common origin from an ancestral gene. The most common GABAA 
receptor contains two α, two β and one γ subunit (α2β2γ), rarely, subunit δ, ε e π can 
substitute γ. Although ρ subunits are classically listed as GABAA receptors subunits, they 
do not coassemble with the other GABAA subunits, but rather form homooligomery 
(Jembrek & Vlainic, 2015). Receptors exclusively formed by ρ subunits have been initially 
classified as GABAC receptors. Subsequently, because of the structural homology with 
GABAA receptors, the International Union of Pharmacology subcommittee on 
nomenclature recommended to consider GABAC receptors as a subtype of GABAA 
receptors, named GABAA-ρ receptors. However, accumulating and ongoing studies  
strongly support the distinct pharmacology, function, genetic and localization of these 
receptors, questioning about the necessity of an effective distinction between GABAA and 
GABAC receptors (Enz, 2001). Since GABAA receptors are pentameric assemblies formed 
by a combination of numerous subunits, a large number of receptor subtypes could occur. 
This great heterogeneity could confirm the great importance of (A)-GABAergic 
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neurotransmission in the fine regulation of neuronal excitability, with the necessity of 
different GABAA receptor subtypes deputed to different functions. Indeed, ongoing studies 
recent successfully demonstrated the possibility of a separation of central effects of 
GABAergic agents, as sedation, anxiolysis and memory enhancement, via the use of 
subtype-selective GABAA agonists (Rudolph & Möhler, 2006); as an example, α2- or α3-
containing GABAA receptors have been reported to specifically provide anxiolysis without 
sedation. Moreover, Seifi et al. (2014) recently described the complexity of the (A)-
GABAergic system in mouse colon, since subtype-specific GABAergic agents displayed a 
wide range of effects on colonic contractility, likely related to the diverse subunit 
composition of GABAA receptors located on populations of enteric neurons. Hence, future 
scientific efforts are needed to establish the functional correlation between the  different 
GABAA receptor subtypes and specific neuronal functions, also in view of developing 
novel GABAA-related therapeutic agents. 
 
 
Figure 21: Schematic representation of a classic α2β2γ GABAA receptor. 
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 Pharmacology 
The GABAA receptors are pharmacologically distinct from the other GABA receptors via 
their sensitivity to the action of drugs as bicuculline, acting as antagonist, and of muscimol, 
acting as agonist. The GABAA receptor binds two molecules of GABA at the interface 
between the α and the β subunits; once bound to GABA, the protein receptor changes 
conformation within the membrane, opening the pore and allowing chloride anions (Cl
−
) to 
flow (Bormann, 2000). As aforementioned, in most of neurons activation of GABAA 
receptors results in inflow of chloride anions with an hyperpolarizing effect,  reducing the 
neuronal excitability. However, in population of neurons sustaining elevated intracellular 
Cl
− 
concentration, as immature and enteric neurons, activation of GABAA receptors results 
in an outflow of chloride depolarizing the membrane potential and thus resulting in 
prominent excitatory effects. Apart the binding sites for GABA, GABAA receptors contain 
binding sites for several important drugs, including benzodiazepines, barbiturates, 
neurosteroids and ethanol, acting as allosteric modulators classically reinforcing the effect 
of GABA (Sieghart, 2015). Moreover, different subtypes of GABAA receptors are 
responsible for two forms of GABA-mediated inhibition, depending on the localization of 
the receptors (Farrant & Nusser, 2005). Synaptic GABAA receptors, localized on the 
postsynaptic membrane, mediate a classical temporary “phasic” inhibition, whilst 
extrasynaptic GABAA receptors, located outside the synapse, mediate a persistent “tonic” 
inhibition. Extrasynaptic GABAA receptors display an higher affinity for GABA compared 
to synaptic GABAA receptors, as well as a reduced desensitization; also, extrasynaptic 
receptors are insensitive to benzodiazepine, but high sensitive to barbiturates, suggesting 
they could be the key targets for anesthetics. 
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4.3.2 GABAB receptors 
GABAB receptors are heterodimeric receptors pharmacologically sensitive to the 
antispastic baclofen (agonist) and phaclofen (antagonist). GABAB receptors are constituted 
by two different subunits containing seven transmembrane domains each: the GABAB1 
subunit, bearing the binding site for GABA, and the GABAB2 subunit, coupled to a G-
protein (Bettler et al., 2004) (Fig.22). Also, GABAB2 subunit is needed to mask an 
endoplasmic reticulum retention signal of GABAB1 and to enhance agonist affinity. 
GABAB receptors are the main responsible for GABA-mediated long term inhibition, 
through their dual presynaptic and postsynaptic localization:  
- Presynaptic GABAB receptors negatively influence and control the release of 
GABA itself (GABAB autoceptors) or other NTs (GABAB heteroceptors; i.e. 
glutamate, noradrenaline, dopamine) through inhibition of voltage-gated Ca
2+
 
channels (Lewis, 2010). Presynaptic GABAB autoceptors are thus involved in a 
negative feedback avoiding excessive release of GABA in the synapse, whilst 
presynaptic GABAB heteroceptors finely regulate the release of numerous 
neurotransmitters, permitting the maintenance of a balance between excitatory and 
inhibitory neurotransmission.  
- Postsynaptic GABAB receptors positively regulate K+ channels causing 
hyperpolarization of the postsynaptic membrane, and so reducing neuronal 
excitability (Gage, 1992).  
 
Although GABAB-dependent inhibitory effect on adenylate cyclase has been also reported 
(Dolphin, 1984), the functional significance of such latter action is still largely unclear. 
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Figure 22: Schematic representation of the GABAB receptor and related major intracellular pathways 
 
4.3.3 GABAC receptors 
As aforementioned, ionotropic GABAC receptors are currently classified as a subclass of 
GABAA receptors, namely GABAA-ρ receptors. However, different studies suggest the 
necessity of a precise distinction of GABAA and GABAC receptors based on 
pharmacological properties, genetics and function (Enz, 2001). GABAC receptors are 
pentameric receptors pharmacologically sensitive to cis-4-aminocrotonic acid (CACA, 
specific agonist) and (1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA, 
specific antagonist). GABAC receptors are entirely composed of ρ subunits (ρ subunits: ρ1-
ρ3), constituting chloride channels as GABAA receptors (Fig.23). Although GABAC 
receptors are primarily expressed in the retina, participating in retinal signal processing 
(Lukasiewicz et al., 2004), evidence for functional GABAC receptors in the spinal cord, 
pituitary, superior colliculus and the gut has been reported (Johnston et al., 2003), 
suggesting that a more detailed functional characterization of GABAC receptors in the 
should be recommended in order to disclose their effective role besides the retina. 
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Figure 23: Schematic representation of the GABAC receptor 
 
4.4 The enteric GABAergic system: 
focus on colonic motility and inflammation 
 
Among the modulatory NTs in the ENS, a plethora of studies addressed γ-aminobutyric 
acid (GABA) as a potential powerful mediator involved in different enteric neural circuits 
underlying GI motility as well as submucosal and mucosal functions (Krantis, 2000; 
Hyland & Cryan, 2010; Auteri et al., 2015) (Fig.24). GABA meet all the criteria to be 
considered an enteric mediator, since GABA-synthesizing enzyme glutamate 
decarboxylase (GAD) has been found in the ENS, particularly in the myenteric plexus, as 
well as the degrading enzyme, GABA transaminase (GABA-T) (Tanaka, 1985; Williamson 
et al., 1995). High affinity membrane GABA transporters have been shown both on enteric 
neurons and enteric glial cells, and GABA release from enteric neurons is calcium- and 
tetrodotoxin-(TTX) dependent (Taniyama et al., 1982). However, to date the exact 
significance of GABAergic signaling in the GI tract is still incompletely understood. 
Regarding the GABAergic neuronal network in the gut, GABAergic neurons have been 
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reported in the myenteric, submucosal and mucosal plexi. In the myenteric plexus, GABA 
has been reported in somatostatin-, NO- and encephalin-containing neurons, whilst 
GABAergic cells in the submucosa and mucosa co-localize with NO or somatostatin 
(Krantis, 2000). GABA is also secreted by mucosal endocrine-like cells, likely G- and D-
cells in the stomach, implying its potential as local paracrine/autocrine mediator (Krantis et 
al., 1994). In addition, a series of studies have demonstrated the presence of GABA 
receptors, GABAA, GABAB and GABAC receptors, both in neuronal and non-neuronal 
cells in the entire GI tract (Poulter et al., 1999; Casanova et al., 2009). In particular, 
classical α2β2γ GABAA receptors are found both in myenteric and submucosal neurons, as 
well as in intestinal epithelial cells. GABAA receptors in the ENS were found to elicit 
depolarizing effects, since enteric neurons maintain prominent intracellular Cl
−
 
concentration, possibly through the action of a sodium-potassium-chloride symporter (Xue 
et al., 2009). The depolarization induced by ionotropic GABAA receptor activation lead to 
an influence on NTs release from both excitatory and inhibitory neurons. Regarding 
metabotropic GABAB receptors, studies in the rat GI tract revealed distribution of GABAB 
receptors in submucosal and myenteric neurons, in the latter mainly on nitrergic neurons. 
However, a large amount of pharmacological evidence showed that the main action of 
metabotropic GABAB receptors in the ENS is the presynaptic inhibition of ACh release via  
inhibition of voltage-sensitive calcium channels (Marcoli et al., 2000). In addition, 
different rat GI epithelial cells from the stomach to the colon possess GABAB receptors 
(Davanger et al., 1994), supporting the possibility of GABA involvement in the regulation 
of gastric functions. Moreover, in the small intestine, many GABAB-immunoreactive cells 
contain 5-HT, supporting their identification as enterochromaffin (EC) cells, and 
suggesting the involvement of GABAB receptors in local secretory and peristaltic reflexes 
(Krantis, 2000). Few studies focused on the localization and functional role of the GABAC 
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receptors in the gut. GABAC receptor subunits have been found in the rat duodenum, ileum 
and colon, in IPANs and nitric oxide synthase (NOS)-immunoreactive neurons (Johnston 
et al., 2003). Interestingly, the specific GABAC agonist CACA was found to induce a 
promoting effect on the release of NO from inhibitory motoneurons in rodents (Zizzo et al., 
2007). Thus, a more detailed characterization of GABAC receptors in the GI tract is needed 
to disclose their effective involvement in the modulation of GI functions. Regarding the 
GABAergic receptor system in humans, GABAB receptor subunits have been found in the 
lower esophageal sphincter (LES), stomach and small intestine (Calver et al., 2000; 
Torashima et al., 2009), whilst no study addressed the localization of ionotropic GABAA 
and GABAC receptors in the human GI tract. Thus, novel investigations addressing the 
enteric GABAergic receptors in humans are absolutely needed to disclose the effective role 
of GABA in the regulation of GI function.  
 
 
Figure 24: GABAergic  innervation in the intestinal  wall. ACh, cholinergic motor neurons; EC; 
Enterochromaffin cells; ENK, Enkephalin; NANC, non adrenergic non cholinergic motor neurons; 5-HT, 5-
hydroxytryptamine; HA, histamine; EC, enterochromaffin cell; NO, Nitric Oxide; PG, prostaglandins. 
(Adapted from Krantis et al., 2000) 
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The involvement of enteric GABAergic signaling on GI motility has been extensively 
reported, disclosing a variety of action of GABA and GABAergic drugs in the different GI 
tract (Auteri et al., 2015). In the stomach, GABAA receptors have been linked to a 
facilitatory effect on non adrenergic non cholinergic (NANC) neurotransmission (Krantis 
et al., 1998), whilst activation of GABAB receptor has been related to a modulatory action 
of GABA on the vagal drive to the stomach, in turn influencing gastric tone and 
contractility (Andrews et al., 1987). In the small intestine, effects of GABA include the 
modulation of both excitatory and inhibitory signaling in the ENS, and, specifically, a fine 
regulation of ACh release in the ileum has been demonstrated (Roberts et al., 1993). 
However, even more interesting is the potential role of GABAergic pathways in the large 
intestine. Indeed, studies addressing the effects of GABA on the colonic mechanical 
activity were closely associated to its action in the modulation of the most important 
physiological colonic motor pattern, the peristalsis. Peristalsis is a reflex controlled by the 
ENS and induced by the mechanical and chemical stimuli determined by intestinal contents 
on the intestinal mucosa. These stimuli induce 5-HT release from enterochromaffin (EC) 
cells, in turn activating intrinsic sensory neurons involved in the initiation of specific 
enteric neural circuits (Grider, 2003). Indeed, peristalsis consists of a neural ascending 
excitation and descending inhibition, leading to a muscular contraction orally and 
relaxation aborally to the stimulated GI tract. The resulting rhythmic and coordinated 
motor behaviour allows the physiological propulsion of luminal contents along the colon. 
Ascending contraction depends on the release of ACh and substance P (SP) from enteric 
excitatory motor neurons, whilst descending inhibition is related to the muscular response 
to mediators released by enteric inhibitory motor neurons, namely NO, VIP, ATP and 
pituitary adenylate cyclase-activating peptide (PACAP). A complex network of enteric 
interneurons, including ACh-, VIP-, NO-, somatostatin- and opioids-containing neurons, is 
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implicated in modulating the peristaltic activity. Different researches reported that 
GABAergic neurons are likely involved in this ENS circuitry underlying the modulation of 
peristaltic activity, although its effective role in regulating the colonic mechanical activity 
are still a matter of debate. Both GABA and the selective GABAB agonist baclofen 
reduced peristaltic propulsion in the rabbit via the modulation of the cholinergic signal 
(Tonini et al., 1989), whilst GABAA receptor blockade induced an inhibitory effect on the 
peristaltic activity, both on ascending contraction and descending relaxation (Grider & 
Makhlouf, 1992). Subsequent studies demonstrated that GABA is able to activate a 
population of VIP/PACAP/NOS interneurons (Grider, 1998), in turn positively influencing 
the release of ACh and substance P from excitatory motor neurons mediating the ascending 
contraction. Also, GABA has been reported to be actively involved in a functional enteric 
network, comprising somatostatinergic and opioidergic neurons, allowing the descending 
relaxation via a promotion of neurotransmitters release from inhibitory motor neurons 
(Grider, 1994). Although these results already suggest the potential importance of 
GABAergic pathways in the modulation of colonic peristalsis, the effective significance of 
GABA signaling in the control of physiologic colonic mechanical activity is still unclear, 
and additional studies are needed to unravel the effective significance of GABA signaling 
on colonic motor patterns. In addition, a recent study by Seifi et al. (2014) demonstrated 
the complexity of the (A)-GABAergic system in mouse colon, since subtype-specific 
GABAergic agents displayed a wide range of effects on colonic contractility, likely related 
to the diverse localization and function of differently composed GABAA receptors on 
populations of enteric neurons. Drugs specifically activating α1-γ2-containing GABAA 
receptors or α4-containing GABAA receptors increased the force of spontaneous 
contractions, agonist at α2-γ2-containing GABAA receptors increased the frequency of 
contractions, whilst activation of α3-γ2- and α5-γ2-containing receptors was associated 
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with decreased force of spontaneous colonic contractions (Seifi et al., 2014). Such finding 
are of particular importance in a therapeutic view, since GABAergic subtype-specific 
drugs could be developed to possibly realize a precise desirable effect in the colonic 
environment avoiding unwanted actions. The precise characterization of GABAergic 
pathways in the regulation of colonic motility could thus lead to the identification of 
pathological modification of GABA signaling in GI motor disorders,  including GI 
disturbances in IBD. Indeed, possible changes of GABAergic signaling in the course of 
inflammatory conditions are potentially linked to the disclosed role of GABA as one of the 
neuromodulators involved in the regulation of immune cell activity and inflammatory 
events, since GABA receptors were found on several immune cells, including DCs, 
macrophages and T cells (Jin et al., 2013). Although GABAergic fibers in the gut are 
mainly interneurons, occurring within the myenteric and submucosal plexus in animal 
models and humans, the presence of GABAergic neuronal cells ramifying within the 
mucosa, and so potentially functionally associated with immune cells in the GALT have 
been reported (Krantis, 2000). Moreover, GABAergic neurons in the submucosa are likely 
to be involved in a ENS circuitry modulating histamine release from mucosal mast cells 
(MacNaughton et al., 1996) supporting the presence of GABA-related enteric 
neuroimmune pathways. Intriguingly, agonists of GABAA receptors have been reported to 
dampen macrophage’s cytokine production and to reduce T-cell proliferation, whilst 
GABAB agonists inhibited both TNF-α production from peripheral blood mononucleated 
cells and IL-6 and IL-12 release from microglia (Bjurstöm et al., 2008; Jin et al., 2013). 
Overall, these effects primarily support a possible anti-inflammatory action of GABA via 
the negative control of major inflammatory processes in different immune cells. 
Accordingly, in vivo studies revealed a positive action of GABA treatment on animal 
models of inflammation. For instance, GABA treatment ameliorates inflammation in a 
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mouse model of rheumatoid arthritis as well as in non-obese diabetic mice (Tian et al., 
2004, 2011). Furthermore, GABAB agonists ameliorated dermatitis in mice (Duthey et al., 
2010), and GABAA agonists improved experimental encefalomielitis (Bath et al., 2010). 
Although scarce investigations have addressed the possible action of GABA on GI 
inflammation, a pioneer study by Dudley et al. (2011) demonstrated that the anti-epileptic 
drug topiramate, possessing GABAA agonism properties, reduces macroscopic and 
microscopic GI inflammatory scores in the 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-
induced rat model of IBD. However, the mechanism underlying topiramate-induced effect 
on IBD inflammation remain unknown, and so further investigations are needed to reveal 
the potential involvement of GABA and GABAergic drugs in the IBD-related 
inflammation. 
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4.5 
Opposite role played by GABAA and GABAB receptors in the 
modulation of peristaltic activity in mouse distal colon 
 
 
4.5.1 Aim 
 
As previously stated, enteric GABA signaling is believed to be involved in colonic 
peristalsis, although its effective contribution is far from being clear. Therefore, the aim of 
this study was to analyze, in vitro, the possible effect of GABA on the colonic mechanical 
activity, using as model the mouse distal colon. In particular, we studied the effects 
induced by GABA receptors recruitment in both isolated circular muscle preparations and 
whole colonic segments, in order to determine their influence both on the spontaneous and 
electrically-evoked colonic contraction and on the experimentally-induced peristaltic 
reflex, respectively. 
 
4.5.2 Materials and Methods 
Animals 
Experiments were performed on adult male C57BL/6 mice obtained from Charles River 
Laboratories (Calco- Lecco, Italy). Animals were kept under environmentally controlled 
condition (ambient temperature 24 °C, humidity 60% and 12 h light/dark cycle) with food 
and water ad libitum. Procedures involving animals and their care were conducted in 
conformity the Italian D.L. no. 116 of 27 January 1992 and associated guidelines in the 
European Communities Council Directive of 24 November 1986 (86/609/ECC). The mice 
were euthanized using isoflurane anesthesia followed by cervical dislocation, and after 
laparotomy the colon was rapidly excised and placed in Krebs solution. Then, whole 
segments of distal colon (about 5 mm proximal to the anus) of approximately 3.5 cm 
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length or circular muscle strips (10 mm in length) were prepared and used for the different 
experiments. 
 
In vitro measurement of colonic peristaltic activity 
A modified Trendelenburg set-up (Figure 25a) was used to induce peristaltic activity in 
isolated colonic segments (Trendelenburg, 2006; Seerden et.al, 2007). Colonic segment 
was mounted horizontally in a 4 ml organ bath filled with warm and oxygenated Krebs 
solution (37 °C, 95% O2 and 5% CO2) (Figure 25b). The aboral end was secured to an 
open, adjustable outlet that could be raised in height. The oral side of the segment was 
connected to a pressure transducer (Statham Mod. P23XL; Grass Medical Instruments, 
Quincy, MA, USA) for the recording of intraluminal pressure differences and to a 
perfusion pump allowing continuous intraluminal infusion of warm and oxygenated Krebs 
solution at a rate of 0.5 ml/min.  
 
 
  
Figure 25 (a): Schematic representation of the Trendelenburg set-up for the in vitro analysis of                    
peristaltic activity.   
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Figure 25 (b): Particular of colonic segment mounted in the Trendelenburg set-up 
 
 
The tissue was allowed to equilibrate for about 20 min and then the outlet was gradually 
moved up to a height of 7.5 cm by increments of 2.5 cm every 20 min. The gradual 
distension of the colonic tissue resulted in rhythmic and repetitive peristaltic contractions 
propagating aborally, which were recorded by the pressure transducer at the oral side of the 
segment as cyclic pressure waves and recorded on ink-writer polygraph (Grass model 7D). 
Time control experiments showed that at an outlet-height of 7.5 cm pressure waves were 
highly reproducible persisting for several hours. In a first series of experiments, tissues 
were exposed to cumulative concentrations of GABA with an incubation time of 5 min per 
concentration. Then, using specific agonists and antagonists for the GABAergic receptor 
subtypes we evaluated the specific contribution of each receptor to the peristaltic activity. 
Each preparation was tested with a single agonist/antagonist, except when otherwise stated. 
 
In vitro analysis of the mechanical activity of colonic circular muscle strips 
 
Segments of distal colon were opened along the mesenteric border and pinned mucosa side 
up. The mucosa was removed by sharp dissection under a microscope and full-thickness 
muscular strips (10 mm in length) were cut in the direction of circular muscle and 
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suspended in a four-channel organ bath containing 10 ml of oxygenated (95% O2 and 5% 
CO2) Krebs solution maintained to 37 °C. The distal end of each strip was tied to an organ 
holder and the proximal end was secured with a silk thread to an isometric force transducer 
(FORT 25, Ugo Basile, Biological Research Apparatus, Comerio VA, Italy). Mechanical 
activity was amplified and digitized via an analog/digital interface (Quad Bridge and 
PowerLab/400, AD Instruments, Ugo Basile, Biological Research Apparatus, Comerio 
VA, Italy), prior being acquired onto a personal computer. The preparations were subjected 
to an initial tension of 500 mg and were allowed to equilibrate for at least 30 min. After the 
equilibration time, preparations were challenged with 10 μM carbachol (CCh) for 2 min, 
until stable responses were obtained. The contractile response to CCh (10μM) was 962.2± 
87.7 mg, n=20. Electrical field stimulation (EFS) was applied from a Grass S88 electrical 
stimulator (Grass Instruments Co., Quincy, Mass, USA) through a stimulus isolation unit 
(SIU5) using direct coupling. Stimuli (0.5 ms, 10 V for 10 s) were delivered via a pair of 
platinum plate electrodes. 4 Hz frequency was chosen to specifically activate cholinergic 
neurons, whilst 32 Hz frequency was selected to elicit a non adrenergic non cholinergic 
(NANC) response in the presence of atropine and guanethidine (1 μM each). GABA or 
GABAergic receptor agonists were tested on EFS responses being applied for 
approximately 5 min at 20 min intervals. GABAergic antagonists were left in contact with 
the tissue at least for 30 min. Each preparation was tested with a single agonist/antagonist, 
except when otherwise stated. Concentrations of the drugs used were determined from 
literature (Zizzo et al., 2007; Rotondo et al., 2010). 
 
Solutions and drugs 
The following drugs were used: atropine sulfate, baclofen, bicuculline, cis-4-aminocrotonic 
acid (CACA), γ-aminobutyric acid (GABA), guanethidine monosulphate, hexamethonium 
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bromide, (1,2,5,6-tetrahydropyridin-4-yl) methylphosphinic acid hydrate (TPMPA), 
tetrodotoxin (TTX), all purchased from Sigma (Sigma-Aldrich, Inc., St. Louis, USA). 
Phaclofen was from Tocris (Tocris Cookson LtD., Avonmouth, UK). Bicuculline was 
dissolved in dimethyl sulphoxide (DMSO), phaclofen in 0.1 N NaOH and all the other 
drugs were dissolved in distilled water. The working solutions were prepared fresh on the 
day of the experiment by diluting the stock solutions in Krebs. The final volume of DMSO 
or NaOH in the organ bath did not exceed 0.1% and control experiments showed that they 
have no effect on the spontaneous contractile activity or on the peristaltic activity. 
 
Data analysis and statistical tests 
Colonic peristaltic activity was assessed for each colonic segment by quantifying the 
maximal amplitude (cm H2O) and the interval (s) between the peaks of two successive 
contractions. The different parameters of peristalsis from five consecutive contractions 
were measured immediately prior to addition of drugs and during treatments. Contractile 
responses to EFS were expressed as a percentage of the contractile response produced by 
10 µM CCh. All data are expressed as means±SEM. The letter n indicates the number of 
experimental animals. Statistical analysis was performed by means of Student׳s t test or by 
means of analysis of variance followed by Bonferroni׳s test, as appropriate. (PRISM, 
version 4.0; GraphPad software Inc., San Diego, CA, USA). A p value of less than 0.05 
was regarded as significant. 
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4.5.3. Results 
Effects of GABA on colonic peristaltic activity in mice 
The gradual distension of distal colonic segments mounted in the Trendelenburg system 
induced a series of  rhythmic peristaltic contractions propagating aborally with a mean 
pressure amplitude of 16 cm H2O and a mean interval of 60 s (Fig. 26). Administration of 
GABA induced diverse effects on peristaltic activity depending on the concentration used. 
At a concentration range from 10 µM to 50 µM, GABA caused a significant increase in the 
amplitude of the peristaltic waves, but it did not significantly modify the interval of 
peristaltic waves (Fig.26). On the other hand, administration of GABA at concentration 
500µM-1mM, induced a significant inhibition of peristaltic activity, reducing the 
amplitude and increasing the interval of peristaltic waves (Fig. 26).  
 
 
Figure 26: GABA effects on peristaltic pressure waves in mouse distal colon. (Top) Original tracings 
showing the distension-induced pressure waves in mouse distal colon in control condition or in the presence 
of GABA 10 μM and GABA 1 mM. (Bottom) Concentration-dependent effects of GABA (10 μM–1 mM) on 
the amplitude and interval of distension-induced colonic peristaltic activity in mouse distal colon. Results are 
expressed as means±S.E.M. (n=12). 
⁎
P<0.05 versus control. 
 
 
CONTROL 
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Interestingly, the excitatory effect of low GABA concentrations were mimicked by 
administration of muscimol (100 µM) (Fig. 27a,b), a selective GABAA-receptor agonist, 
and antagonized by pretreatment with bicuculline (10μM), a selective GABAA-receptor 
antagonist. Intriguingly, bicuculline per se was able to reduce the amplitude of peristaltic 
waves (Fig. 27a). On the other hand, the inhibitory effect of higher concentration of GABA 
were mimicked by the selective GABAB receptor agonist baclofen (100 µM), and 
prevented by phaclofen (10 µM), GABAB-receptor antagonist (Fig. 27a,b). Phaclofen per 
se showed no effect on peristaltic activity. GABAC receptor agonist CACA (100 µM) and 
GABAC receptor antagonist TPMPA (10 µM)  did not influence the amplitude and interval 
of colonic peristaltic waves (Fig. 27a,b).  
 
 
Figure 27 (a): Effects of GABA and of selective GABA receptor antagonists on peristaltic pressure waves in 
mouse distal colon. Histograms showing the effects induced by 10 μM GABA (left) or by 1 mM GABA 
(right) on the amplitude of colonic peristaltic activity in mouse distal colon in the absence or in the presence 
of bicuculline (10 μM, n=4 each), phaclofen (10 μM, n=4 each) and TPMPA (10 μM, n=3 each) GABAA, 
GABAB and GABAC receptor antagonists respectively. Results are reported as means±S.E.M. The graphed 
values for the control bars are the means of the data obtained before each treatment. 
⁎
P<0.05 when compared 
to its own control. 
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Fig. 27 (b): Effects of selective GABA receptor agonists on peristaltic pressure waves in mouse distal colon. 
Original tracings showing the effects induced by muscimol (100 μM), baclofen (100 μM) or CACA 
(100 μM), GABAA, GABAB and GABAC receptor agonists respectively, on the distension-induced pressure 
waves in mouse distal colon.  
 
 
Effect of GABA on spontaneous and electrically-evoked colonic circular muscle 
contractions in mice 
 
Circular muscular strips isolated from mouse distal colon, once placed in the organ bath 
and after a period of  stabilization, developed a spontaneous mechanical activity consisting 
of rhythmic contractions with an amplitude of 245.0±15.2 mg and a frequency of 4.4±0.3 
cpm (contractions per minute) (n=20). Administration of GABA or GABAergic drugs did 
not influence the  amplitude and frequency of spontaneous contractile activity (data not 
shown). Electrical field stimulation (EFS: 0.5 ms, 4 Hz, 10 V for 10 s) elicited a biphasic 
response: a low in amplitude transient muscular relaxation followed by a high in amplitude 
contraction (439.8± 31.0 mg, n=24), the latter depending on the release of ACh from 
enteric neurons (Zizzo et al., 2011). Treatment with GABA diversely influenced the 
neurally-evoked cholinergic contractions depending on the concentration utilized. GABA 
at 10–50 µM concentrations significantly increased the neurally-evoked cholinergic 
contractile responses to EFS, whilst in the range of 500 µM–1 mM GABA caused a 
significant decrease of the same responses (Fig. 28). 
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Figure 28: Effects of GABA on cholinergic electrically-evoked responses in the circular muscle of mouse 
distal colon. (Top) Original tracings showing the effects induced by 10 μM GABA or by 1 mM GABA on 
the cholinergic electrically-evoked responses in the circular muscle strips of mouse distal colon. Electrical 
field stimulation was delivered at 0.5-ms pulse, 4 Hz, 10 V for 10 s. (Bottom) Histogram showing the 
concentration-dependent effects induced by GABA (10 μM–1 mM) on the cholinergic responses to electrical 
field stimulation in the circular muscle strips of mouse colon. Data are means±S.E.M and are expressed as a 
percentage of the amplitude of contraction induced by 10 μM CCh taken as 100%. The graphed values for 
the control bars are the means of the data obtained before each treatment. ⁎P<0.05 when compared to the 
respective own control. 
 
 
GABA-induced excitatory effect was mimicked by muscimol (100 μM), the GABAA 
receptor agonist, and blocked by pretreatment of the samples with bicuculline (10 µM), the 
selective GABAA receptor antagonist, which also caused per se a reduction of the 
amplitude of the EFS-induced cholinergic contractions (Fig. 29-30). On the contrary, 
bicuculline did not antagonize the inhibitory effects induced by GABA 500 µM–1 mM. 
Indeed, such inhibitory effects were prevented by pre-incubation with the selective 
CONTROL 
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GABAB-receptor antagonist, phaclofen (10 µM), and mimicked by the GABAB receptor 
agonist baclofen (100 μM). Phaclofen per se was not able to affect neither the GABA-
induced excitatory effects nor the neurally-evoked cholinergic contractions (Fig. 29-30). 
As for the induced peristaltic activity, GABAC-receptor agonist and  antagonist  did not 
affect the responses (Fig. 29-30).  
 
 
Figure 29: Effects of selective GABA receptor agonists on cholinergic electrically-evoked responses in the 
circular muscle of mouse distal colon. Original tracings showing the effects of muscimol (100 μM), baclofen 
(100 μM) or CACA (100 μM), GABAA, GABAB and GABAC receptor agonists respectively, on neurally- 
evoked cholinergic contraction in circular muscle of mouse distal colon 
 
 
 
Figure 30: Histograms showing the effects induced by 10 μM GABA (left) or by 1 mM GABA (right) on the 
neurally evoked cholinergic contraction (0.5-ms pulse, 4 Hz, 10 V for 10 s) in the circular muscle of mouse 
colon in the absence or in the presence of bicuculline (10 μM, n=4 each), phaclofen (10 μM, n=4 each) and 
TPMPA (10 μM, n=3 each), GABAA, GABAB and GABAC receptor antagonists respectively. Results are 
reported as means±S.E.M and are expressed as a percentage of the amplitude of contraction induced by 10 
μM CCh taken as 100%. ⁎P<0.05 when compared to the respective own control. 
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Pretreatment of the samples with hexamethonium (100 µM), nicotinic receptor antagonist, 
which per se did not modify the neurally-evoked cholinergic contractions, antagonized the 
inhibitory effects induced by high GABA concentrations, without affecting the excitatory 
effects induced by the lower ones (Fig. 31). The adrenergic blocker guanethidine (1 µM), 
(Fig. 31) did not influence neither the excitatory nor the inhibitory GABA-induced effects 
on the EFS-evoked cholinergic contractions.  
 
 
Figure 31: Histograms showing the effects induced by 10 μM GABA (left) or by 1 mM GABA (right) on the 
neurally evoked cholinergic contraction (0.5-ms pulse, 4 Hz, 10 V for 10 s) in the circular muscle of mouse 
colon in the absence or in the presence of the nicotinic receptor antagonist, hexamethonium (HEXA 
100 μM, n=4) or of the adrenergic neuron blocking agent, guanethidine (1 μM, n=3). Results are reported as 
means±S.E.M and are expressed as a percentage of the amplitude of contraction induced by 10 μM CCh 
taken as 100%.
⁎
P<0.05 when compared to its own control. 
 
 
 
Moreover, in the presence of atropine and guanethidine, to induce non adrenergic non 
cholinergic (NANC) conditions, EFS was characterized by a more evident initial transient 
inhibitory phase followed by a rebound contraction, the latter with an amplitude at 32 Hz 
of 449.9±24.3 mg (n=6). GABA or GABAergic drugs failed to affect both the inhibitory 
phase of the EFS and the following NANC contractions (Fig. 32).  
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Finally, GABA or GABAergic drugs had no effect on the amplitude of the contractions 
induced by the muscarinic agonist carbachol (10 µM). 
 
 
Figure 32: Original tracings showing the non-adrenergic, non-cholinergic (NANC) responses to electrical 
field stimulation (0.5 ms pulse, 32 Hz, 10 V for 10 s) in circular muscle of mouse distal colon in control 
conditions and in the presence of 10 μM GABA or 1 mM GABA. Note that GABA at any concentration 
affected neither the early inhibitory phase nor the following contraction. 
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4.5.4 Discussion and conclusions 
Our experimental results indicates that GABA in mouse distal colon is able to modulate 
peristaltic activity via the regulation of ACh release from enteric excitatory cholinergic 
neurons, interacting  with GABAA or GABAB receptors. Low GABA concentrations (10–
50 µM) activate GABAA receptors resulting in an increase of ACh release and peristaltic 
activity. On the other hand, higher GABA concentrations (500 µM–1 mM) activate 
GABAB receptors, and their activation likely overrides GABAA receptors effects, 
ultimately reducing ACh release and peristaltic activity. As previously stated, controversial 
data are reported about the role of GABA in the regulation of colonic peristalsis. GABA 
and baclofen, the selective GABAB agonist, were found to inhibit peristaltic activity via a 
negative influence on the cholinergic signaling (Tonini et al., 1989), whilst blockade of 
GABAA receptors was reported to elicit an inhibitory effect on peristalsis acting both on 
the ascending contraction and descending relaxation via a negative action on ACh and VIP 
release, respectively (Grider & Makhlouf, 1992). Moreover, studies in rat distal colon have 
provided evidence for an in-depth contribution of GABAergic signaling in the neuronal 
network governing peristalsis. GABA activates a VIP/PACAP/NOS interneurons, in turn 
inducing the release of ACh and substance P from excitatory motor neurons allowing the 
ascending contraction (Grider, 1998). Also, an interplay between GABAergic 
somatostatinergic and opioidergic neurons seems to be required for a positive regulation of 
neurotransmitters release from inhibitory motor neurons related to descending relaxation 
(Grider, 1994). Our study integrated this previous findings underlining a possible 
contribution of GABA in the modulation of enteric cholinergic neurotransmission in the 
mouse colon. Our experimental data show that different concentration of GABA induced 
the recruitment of different GABA receptors subtypes, causing opposite effects on the 
peristaltic activity of mouse distal colon. Low GABA concentrations lead to activation of 
 
87 
 
GABAA receptors inducing an increase in the amplitude of the colonic peristaltic waves, 
being such effect mimicked by the GABAA agonist muscimol. The sensitivity of such 
effect to pre-treatment of sample with the selective GABAA receptor antagonist 
bicuculline, but not with GABAB or GABAC receptor antagonists, confirms the 
involvement of GABAA receptors in the observed action. Interestingly, bicuculline per se 
reduced the amplitude of peristaltic waves suggesting that GABAergic neurons could be 
physiologically involved in the peristaltic reflex, exerting a tonic excitatory effect via 
GABAA receptors likely sited on excitatory neural pathways. So, in contrast with data 
obtained in rabbit colon or guinea pig ileum where GABAA receptors were unlikely to play 
a major role in sustaining peristalsis (Tonini et al., 1989a and Tonini et al., 1989b), in 
mouse colon GABAA receptors seems of importance in mediating a tonic positive 
influence on colonic propulsive activity. On the other hand, high GABA concentrations 
could activate GABAB receptors, causing a decrease in peristaltic activity. Inhibitory 
mechanisms associated with activation of GABAB receptors have been reported in other 
animal species, including humans (Gentilini et al., 1992; Hyland and Cryan, 2010).  
To in-depth investigate, in our experimental setting, the enteric network possibly 
influenced by GABAergic signalling, nerve-evoked responses to electrical field stimulation 
were studied in circular muscle strips isolated from mouse distal colon. Data from such 
experiments indicate that GABA specifically modulate the amplitude of the electrically-
evoked cholinergic contractile responses, whilst it did not influence the non-adrenergic 
non-cholinergic excitatory and inhibitory responses. In addition, GABA and GABAergic 
drugs did not affect carbachol-induced contractions, suggesting no changes in the 
sensitivity of muscle cells to muscarinic activation and consequently implying that GABA-
related effects on cholinergic signaling involve prejunctional mechanisms. Once more, 
GABA recruited different receptors in relation to the concentration: GABAA receptors 
 
88 
 
were activated by low concentration of GABA (10–50 µM), causing an enhancement of 
electrically-induced cholinergic contractions (and so ACh release). On the contrary, 
GABAB receptors are activated in the presence of higher GABA concentrations (500 µM–
1 mM), inducing a depression of cholinergic contraction (e.g. a reduced ACh release). 
Hence, regulation of cholinergic activity seems the mechanism by which GABA regulates 
peristaltic activity in mouse colon, influencing the contractile activity of colonic circular 
muscle. Of note, the excitatory effects of GABA are not modified by pre-treatment with 
the ganglionic blocker hexamethonium, nicotinic receptor antagonist, suggesting that 
GABAA receptor activation likely involves a direct regulation of cholinergic motoneurons. 
Instead, GABA-induced inhibitory effects on the cholinergic activity are hexamethonium-
sensitive, implying the activation of a more complex network involving neuronal nicotinic 
receptors and so cholinergic interneurons. Finally, the effects of GABA were not modified 
by guanethidine, indicating no influence of GABA on adrenergic sympathetic terminals. 
However, we cannot completely exclude the hypothesis that GABA may also indirectly 
regulate ENS signaling, and then peristaltic activity, via modulation of the release of 
enterochromaffin cells-derived mediators such as serotonin, as previously reported in 
guinea-pig small intestine (Schworer et al., 1989). Thus, further studies are needed to solve 
this issue. Despite the effects of GABA and GABAergic drugs on the response to electrical 
stimulation of enteric nerves, spontaneous mechanical activity was not significantly 
affected by the same drugs, producing no effect neither on the basal tone nor on the 
amplitude and frequency of spontaneous contractile activity.  
Regarding the sensitivity of GABA receptor to different concentration of GABA, some 
evidence reported that GABAA receptor could be more sensitive than GABAB receptors to 
activation by GABA. For instance, saturation binding studies outer neocortical layers of rat 
yielded a dissociation constant for GABAA receptors of about 90 nM and for GABAB 
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receptors of about 340 nM (Chu et al., 1990). Thus, we can speculate that both GABAA 
and GABAB receptors are activated at 500 μM – 1 mM GABA concentrations, but the 
effect of GABAB receptor could completely dominate or override GABAA receptor effects 
on cholinergic transmitter release, in turn resulting in a final inhibitory action. Lastly, 
previous experiments in our laboratory have reported the presence of functional GABAC 
receptor in mouse duodenum mediating inhibitory responses to GABA (Zizzo et al., 2007). 
However, in the present experiment in the mouse colon, as in the stomach (Rotondo et al., 
2010), we did not reveal any involvement of GABAC receptors supporting a region-
specific localization and function of the different GABA receptor subtypes. In conclusion, 
the present work provides evidence for a functional role of GABA in mouse colonic 
peristalsis, displaying a tonic facilitatory effect of GABA via activation of GABAA 
receptors likely located on excitatory nerve pathways. Changes in enteric GABA 
concentration as by local production from commensal intestinal microbiota (Barrett et al. 
2012) or potentially in intestinal inflammatory diseases commonly associated with 
modification in ENS signaling, as IBD (Mawe, 2015; Lakhan & Kirchgessner, 2010) could 
result in the activation of GABAB receptors and in turn in a negative influence on colonic 
motility. Thus, novel researches addressing possible changes of the enteric GABA 
concentration and GABAergic signaling in IBD could reveal the possible contribution of 
GABA in the observed dysfunction of colonic motor activity in these pathologies. In 
addition, given the previously described immunomodulatory actions of GABA (Jin et al., 
2013), it could be possible to speculate that modification in the GABAergic signaling 
would result in modulation of immune activity in IBD. Thus, the investigation of the effect 
of GABA and GABAergic drugs in the contest of IBD is a necessary step to clarify the 
whole potential contribution of enteric GABA in the physiopathology of IBD.  
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CHAPTER 5 
General discussion 
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are 
invalidating inflammatory disorders affecting the GI tract, characterized by a chronic 
inflammatory reaction associated with relapse alternated to periods of clinical remission. A 
plethora of factors is believed to be involved in initiation and sustainment of symptoms, 
including genetic susceptibility, altered intestinal permeability, changes in intestinal 
microbiota, pathological alteration of immune pathways (Hanauer, 2006). Ongoing 
researches are also demonstrating the complex interplay among these factors, reinforcing 
the definition of IBD as composite multifactorial pathologies and suggesting that 
increasing scientific efforts are needed to clarify the physiopathology of IBD in order to 
develop effective therapeutic strategies.  
Keeping in mind this objective, novel insights are emerging from studies addressing the 
involvement of the enteric nervous system (ENS), “the brain in the gut” responsible for the 
fine modulation of most GI functions, in IBD (Di Giovangiulio et al., 2015). Indeed, the 
large amount of neurotransmitters and mediators constituting part of the ENS network are 
strictly involved in intestinal homeostasis, ensuring physiological GI processes as 
secretion, motility, regulation of local blood flow, nutrient absorption, pain signaling. 
Importantly, after that increasing evidence pointed out the possibility of modulation of 
immunity by neural mediators (“nerve-driven immunity”, Pacheco et al., 2012), parallel 
researches have addressed the possible existence of neuroimmune pathways in the ENS 
(Genton, 2003). Indeed, nerve fibers of the ENS have been reported to extend throughout 
the intestinal lamina propria and epithelium, being thus potentially functionally associated 
with immune cells belonging to the Gut-Associated Lymphoid Tissue (GALT). Starting 
from this bases, several enteric mediators including neuropeptides, serotonin and ACh 
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have been reported to influence intestinal inflammation (Oshima et al., 1999; Vu et al., 
2014), with a pro- or anti-inflammatory actions, suggesting the ENS as a source of 
substances potentially involved in the modulation of local immune processes in 
physiologic or pathologic conditions. Concerning IBD, the investigation of the link 
between IBD symptoms and ENS mediators represent an entire new field potentially 
leading to the definition of novel effective therapies for these severe disorders. Indeed, 
changes in signaling of enteric mediators could contribute both directly to the 
inflammatory event in IBD or indirectly to the impairment of different GI functions, 
especially the defects in intestinal motor patterns which are likely associated with severe 
IBD symptoms, as diarrhea, weight loss and malabsorption. 
Different studies have provided evidence for Angiotensin II (Ang II) and γ-aminobutyric 
acid (GABA) as novel enteric mediators involved in the ENS signaling for the control of 
bowel motility, as well as in several major processes including secretion and absorption for 
Ang II and gastric acid secretion, pain signaling and colon carcinogenesis for GABA (Garg 
et al., 2012; Auteri et al., 2015). Interestingly, both mediators have been recently linked 
also to the control of inflammatory events (Katada et al., 2008; Jin et al., 2013), suggesting 
that an in-depth investigation on such substances could lead to the comprehension of their 
contribution in intestinal inflammatory disorders, as Inflammatory Bowel Disease, and, in 
turn, to their identification as potential novel pharmacological targets. Regarding Ang II, 
the experimental data presented in this study pointed out that IBD-related inflammation is 
associated with changes in the functional role of Ang II in the modulation of colonic 
mechanical activity. First, Ang II induced contractile effects in colonic muscle strips from 
both controls and animal model of IBD, but the amplitude of Ang II-induced contraction 
was significantly lower in the latter. In addition, in control animals, contractile effects were 
solely the result of activation of AT1 receptors, whilst, in preparations from inflamed 
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animals, AT1 receptors were still responsible for Ang II-mediated contraction, but the 
observation that the AT2 receptor antagonist, PD123319, significantly increase the 
amplitude of Ang II-mediated contractile effects lead to the hypothesis that tonic activation 
of AT2 receptors in the course of inflammation causes an inhibitory effect on Ang II-
mediated contraction. Experimental results suggest that the inhibitory effect would be 
related to activation of AT2 receptors located on inhibitory nitrergic neurons in the ENS, in 
turn counteracting the AT1-dependent excitatory effect. The observation of changes in Ang 
II-mediated effect between controls and inflamed animals could represent a major finding, 
suggesting an effective participation of Ang II and the local renin-angiotensin system 
(RAS) in the GI tract in IBD physiopathology. In addition, considering that the effective 
role of AT2 receptors is still largely unclear, the specific activation of AT2 receptors solely 
in experimental inflammation points out and confirm previous studies on the connection 
between AT2 receptors and inflammatory conditions (Sabuhi et al., 2011). In particular, 
our study underlined that tonic activation of AT2 receptors would participate in 
inflammation-associated inhibition of GI motility, likely via a pathological promotion of 
nitrergic signaling in the ENS. Experiments using the AT2 receptor antagonist, PD123319, 
demonstrated that tonically-activated AT2 receptors dampen the amplitude of colonic 
phasic contractions, reduce the Ang II-induced contractions of enteric smooth muscle and, 
interestingly, decrease the contractile and relaxant responses to the muscarinic agonist 
carbachol and β2-adrenergic agonist Isoproterenol. This latter observations imply that AT2 
receptor signaling could also induce a dysfunction of smooth muscle contractile properties, 
although the exact mechanism underlying such modification requires novel investigation. 
Thus, novel researches could reveal that pharmacological targeting of AT2 receptors would 
represent a novel therapeutic strategy aiming to restore normal GI motor patterns in IBD, 
extending the current knowledge about IBD physiopathology. Also, exploration of the 
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comprehensive role of AT2 receptors could reveal their involvement in the modulation of 
immune cell activity and inflammation, reinforcing the current evidence about the role of 
Ang II as inflammatory mediator in the GI tract (Garg et al., 2014).  
Regarding GABA, the results of our study in mouse colon showed that, in physiological 
conditions, GABA could act as modulator of the cholinergic signaling required for 
peristalsis and, particularly, a dual action of GABA coupled to activation of GABAA or 
GABAB receptors have been disclosed. Indeed, low GABA concentrations (10-50 μM) 
induced the activation of GABAA receptors, promoting ACh release from cholinergic 
motor neurons in turn responsible for colonic circular muscle contractions. Accordingly, in 
vitro peristalsis experiments revealed a promoting effect of low GABA concentration, as 
well as of the selective GABAA agonist muscimol, on the amplitude of experimentally-
induced colonic peristaltic waves. Of note, administration of bicuculline, the selective 
GABAA receptor antagonist, inhibited per se both ACh release and in vitro peristalsis, 
suggesting that a tonic activation of GABAA receptor could physiologically occur, 
inducing a facilitatory effect on cholinergic signaling and sustaining peristalsis. On the 
other hand, higher GABA concentrations activate GABAB receptors, causing opposite 
effects: particularly, they reduced ACh release via an indirect pathway likely involving 
cholinergic interneurons, in turn resulting in a diminished EFS-induced cholinergic 
contractions of colonic circular muscle strips. Accordingly, such high GABA 
concentrations, as well as the selective GABAB receptor agonist baclofen, reduced the 
amplitude and increased the interval of peristaltic waves. Actually, we can speculate that 
high GABA concentrations could activate both GABAA and GABAB receptors, but the 
inhibitory effect of GABAB receptors would override the excitatory effect of GABAA 
receptors, resulting in the observed inhibitory action. Interestingly, the modulation of 
enteric cholinergic signaling in the ileum by the opposite effect of GABAA (increase of 
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ACh release) and GABAB (decrease of ACh release) receptors activation have been 
pointed out by different research groups (Roberts et al., 2003; Takeda et al., 1989), whilst 
the possible modulation of the cholinergic signaling by GABA in the colon was not 
entirely clear. Indeed, effect of GABA in the colon has been primary linked to the 
modulation of NANC signaling, being likely involved in enteric neuronal network 
promoting the release of NANC mediators required for circular muscle relaxation (Grider 
1994). However, the involvement of GABA in the excitatory cholinergic and tachykinergic 
input for longitudinal muscle contraction in peristalsis has been also suggested by studies 
in rat colon (Grider, 1998). Our study integrates these previous data demonstrating the fine 
modulation by GABA of the cholinergic signaling required for colonic circular muscle 
contraction in peristalsis. GABAA receptors seems to be tonically activated by low GABA 
concentrations in physiological conditions, promoting peristalsis through a direct 
excitatory effect on ACh release from cholinergic motor neurons. On the contrary, an 
increase in enteric GABA would activate GABAB receptors within a more complex enteric 
neuronal network, ultimately decreasing cholinergic signaling and inhibiting peristalsis. 
Such changes in GABA-mediated action depending on the concentration and GABA 
receptor subtypes activated would be of importance in pathological conditions; especially, 
since different researches have reported the possibility of GABA production from 
commensal microbiota (Barrett et al., 2012), it is possible to speculate that in pathological 
conditions associated with changes in the composition and function of intestinal 
microflora, as Inflammatory Bowel Disease (Hold et al., 2014), potential modifications in 
microbiota-derived GABA would influence the ENS circuitry and in turn GI motility. 
Especially, our data pointed out that increased GABA content would negatively influence 
colonic mechanical activity, dampening the peristaltic reflex. Thus, an in-depth 
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investigation of the enteric GABAergic system in IBD should be recommended to reveal 
its potential contribution in IBD-associated dysmotility.  
Interestingly, GABA has been recently identified as a neuroimmune modulator capable of 
influencing the activity of immune cells by binding to specific GABA receptors on their 
surfaces (Jin et al., 2013). Accordingly, GABA and GABAergic agents have been reported 
to counteract inflammation in rheumatoid arthritis, experimental encefalomielitis and 
dermatitis animal model (Tian et al., 2011; Bhat et al., 2010; Duthey et al., 2010). 
However, pro-inflammatory action of GABA has been also described in psoriasis, (Nigam 
et al., 2010) suggesting that novel investigations are needed to determine the effective 
immunomodulatory properties of the GABAergic system. Regarding GI inflammation, it 
has been shown, via metabolomic analysis, that disease recurrence and luminal levels of 
GABA are correlated in Clostridium difficile (Cd)-induced colitis (Dann et al., 2014 
abstract). Also, administration of GABA in drinking water seems to exacerbate Cd-related 
inflammation, altering immune response to the infection. In parallel, the same group 
showed that administration of GABA in drinking water could also worsen colitis induced 
in mice by administration of dextran sulfate sodium (DSS), an established model of IBD 
(Dann et al. 2015, abstract). In contrast, Dudley et al. (2011) demonstrated that in the 
TNBS rat model of IBD, oral treatment with topiramate, an anti-epileptic drugs possessing 
GABAA agonistic properties, ameliorate macroscopic and microscopic inflammation-
related damages. Thus, these pioneer studies suggest that characterization of the role of 
GABA and its receptors in the contest of intestinal inflammation should be recommended 
also for exploring the immunomodulatory properties of the GABAergic system.  
In conclusion, results present in this thesis indicate that modification in the local RAS and 
Ang II role in the ENS circuitry could contribute to the colonic dysmotility associated with 
Inflammatory Bowel Disease, and represent a potential novel pharmacological target for 
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IBD treatment. An investigation on the immunomodulatory role of Ang II in IBD, 
especially associated with AT2 receptors activation, could represent the next step for a 
whole comprehension of the function of local RAS in intestinal inflammation. In addition, 
the disclosed role of enteric GABA as modulator of cholinergic signaling involved in the 
colonic peristaltic activity would represent the scientific rationale for exploration of its 
function in the contest of inflammation-induces defective colonic motor pattern. Once 
more, pioneer studies in literature (Dann et al., 2014, 2015; Dudley et al., 2011) suggest 
that investigation of the potential immunomodulatory properties of GABA in GI 
inflammation should be also recommended, in order to depict its whole function in 
intestinal inflammatory disorders.  
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